First Insights into microbial changes within an Inflammatory Bowel Disease Family 1 **Cohort study** 2

- Philipp Rausch¹*, Ilka Ratjen^{2,3,4}*, Lukas Tittmann^{2,3}, Janna Enderle^{2,5}, Eike Matthias 3 Wacker¹, Kathrin Jaeger^{2,3}, Malte Christoph Rühlemann¹, Katrin Franzpötter², Pierre Ellul⁶, 4
- Robert Kruse⁷, Jonas Halfvarson⁷, Dirk Roggenbuck^{8,9}, David Ellinghaus¹, Gunnar Jacobs^{2,3}, 5
- Michael Krawczak¹⁰, Stefan Schreiber^{1,11}, Corinna Bang¹, Wolfgang Lieb^{2,3*}, Andre Franke^{1*} 6
- 7 *denotes equal contribution
- ¹Institute of Clinical Molecular Biology, University Hospital Schleswig-Holstein, University 8 9 of Kiel, Kiel, Germany
- ²Institute of Epidemiology, University Hospital Schleswig-Holstein, University of Kiel, Kiel, 10
- 11 Germany
- 12 ³ popgen biobank, University Hospital Schleswig-Holstein, University of Kiel, Kiel, Germany
- ⁴ Department of Internal Medicine II, University Cancer Center Schleswig-Holstein, 13
- 14 University Hospital Schleswig-Holstein, Kiel, Germany
- ⁵ Institute of Human Nutrition and Food Science, University of Kiel, Kiel, Germany 15
- 16 ⁶ Division of Gastroenterology, Department of Medicine, Mater Dei Hospital, Malta
- ⁷ Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, 17
- Örebro, Sweden 18
- ⁸ Institute of Biotechnology, Faculty Environment and Natural Sciences, Brandenburg 19 University of Technology Cottbus-Senftenberg, Germany 20
- ⁹ Medipan/GA Generic Assays GmbH, Ludwig-Erhard-Ring 3, 15827 Dahlewitz, Germany 21
- ¹⁰ Institute of Medical Informatics and Statistics, University Hospital Schleswig-Holstein, 22
- University of Kiel, Kiel, Germany 23
- ¹¹ Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany 24
- Correspondence: Prof. Dr. Andre Franke, Christian-Albrechts-University of Kiel, 26
- University Hospital Schleswig-Holstein, Institute of Clinical Molecular Biology, Rosalind-27
- Franklin-Str. 12, 24105 Kiel, Germany; a.franke@ikmb.uni-kiel.de 28
- Abbreviations used: CD-Crohn's disease; IBD-inflammatory bowel disease; IC-informed 29
- consent; UC-ulcerative colitis; uIBD-undetermined inflammatory bowel disease, MD-index-30
- Microbiome dysbiosis index; GMHI-General Microbiome Health Index; PRS-Polygenic Risk 31 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- 32

33 ABSTRACT

Background: The prospective Kiel Inflammatory Bowel Disease (IBD) Family Cohort Study 34 (KINDRED cohort) was initiated in 2013 to systematically and extensively collect data and 35 biosamples from index IBD patients and their relatives (e.g., blood, stool), a population at 36 high risk for IBD development. Regular follow-ups were conducted to collect updated health 37 and lifestyle information, to obtain new biosamples, and to capture the incidence of IBD 38 39 during development. By combining taxonomic and imputed functional microbial data collected at successive time points with extensive anthropometric, medical, nutritional, and 40 41 social information, this study aimed to characterize the factors influencing the microbiota in health and disease via detailed ecological analyses. 42

Results: Using two dysbiosis metrics (MD-index, GMHI) trained on the German KINDRED 43 cohort, we identified strong and generalizable gradients within and across different IBD 44 cohorts, which correspond strongly with IBD pathologies, physiological manifestations of 45 inflammation (e.g., Bristol stool score, ASCA IgA/IgG), genetic risk for IBD, and general risk 46 of disease onset. Anthropometric and medical factors influencing transit time strongly modify 47 bacterial communities. Various Enterobacteriaceae (e.g., Klebsiella sp.) and opportunistic 48 Clostridia pathogens (e.g., C. XIVa clostridioforme), characterize in combination with ectopic 49 oral taxa (e.g. Veillonella sp., Cand. Saccharibacteria sp., Fusobacterium nucleatum) the 50 distinct and chaotic IBD-specific communities. Functionally, amino acid metabolism and 51 52 flagellar assembly are beneficial, while mucolytic functions are associated with IBD.

53 Conclusions: Our findings demonstrate broad-scale ecological patterns which indicate drastic 54 state transitions of communities into characteristically chaotic communities in IBD patients. 55 These patterns appear to be universal across cohorts and influence physiological signs of 56 inflammation, display high resilience, but show only little heritability/intrafamily 57 transmission.

58

59 Keywords: Kiel Inflammatory Bowel Disease Family cohort, epidemiology, microbiota, 16S,
60 dysbiosis

61

62 INTRODUCTION

Inflammatory bowel disease (IBD), with the most common manifestations of Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic, relapsing inflammation of the gastrointestinal tract [1] resulting from a complex interplay of genetic, lifestyle, and environmental factors [2–4]. The incidence and prevalence of IBD are rising in many parts of the world [5,6], and the highest incidences are currently reported in North America and Europe [6,7], while short-term projections expect a prevalence of 1% in high-income countries by the year 2030 [8].

Clustering of IBD cases within families is not uncommon, suggesting a significant 70 71 contribution of shared genes and lifestyle or environmental factors to IBD susceptibility [4,9-12]. First-degree relatives of IBD patients have a 3- to 20-fold greater risk of developing the 72 disease themselves than does the general population [4,11,13,14]. In particular, for siblings of 73 IBD patients, estimates of the relative disease risk range from 10 to 50 [15]. Meta-analyses 74 75 and genome-wide association studies (GWAS) have identified 320 loci associated with either CD or UC or both [16]. Most disease-related genes and pathways are thought to influence 76 disease risk by altering the epithelial barrier, the gut microbiota, or the inflammatory process 77 in general [4,17–20]. Moreover, familial aggregation of IBD has been suggested to be a risk 78 79 factor for a more aggressive course of the disease, earlier disease onset, and greater need for treatment [21,22], while disease risk in families with IBD cases is generally increased [23] 80 81 and can be further evaluated by polygenic risk scores derived from the accumulated genetic 82 knowledge of the disease [24].

Most prior studies on IBD risk factors used a classical case-control design, comparing IBD 83 84 patients to healthy controls. However, the molecular alterations or lifestyle factors that precede or predict the pre-clinical onset of IBD can only be identified reliably in prospective 85 studies that collect health-related information and biomaterials from unaffected or preclinical 86 87 individuals over time. Given the relatively low IBD incidence in the general population and the high familial risk for IBD, a family-based prospective study represents a more efficient 88 study design than a population-based study. However, due to the high costs of maintenance, 89 infrastructure, participant commitment, and long run-time, this type of study design is rare but 90 91 offers great potential [23]. Thus, in 2013, the Inflammatory Bowel Disease Family Cohort 92 (KINDRED cohort), the so-called KINDRED cohort, was initiated in Kiel (Germany) to systematically collect disease-relevant data from IBD patients and their healthy relatives. The 93 main objectives of the study were (i) to identify lifestyle factors and biomarkers that 94 95 predispose patients to, or predict, the development of IBD and (ii) to characterize the longterm clinical course of IBD patients. To this end, comprehensive and high-quality biomaterial 96 (blood, stool, hair) as well as detailed health-related, lifestyle, sociodemographic, and kinship 97 information was collected from the participants of this study. Regular follow-ups are 98 99 performed (approximately every 2 years), which are embedded into a long-term follow-up 100 program for healthy relatives with respect to IBD onset.

One main driver of IBD has been identified in the microbial community inhabiting the intestinal tract. Various human population studies and animal experiments have identified a multitude of ways in which the microbiome varies and interacts with its host, eventually leading to and becoming indispensable for the development of intestinal inflammation [25]. One current hypothesis is that dysbiosis, a shift in the balance of a beneficial microbial community as a whole in favor of a proinflammatory community, eventually leads to and sustains intestinal inflammation via metabolic and immunologic alterations but not single taxa

[25]. These community shifts can result from disturbances introduced through environmental 108 and lifestyle factors, diet, hygiene, medication, or even the host's genetic makeup [25-27]. 109 However, the development of inflammation is a nonlinear and often long-lasting process that 110 can persist preclinical (perceived healthy), although inflammation may already fester [28]. 111 112 Analyzing early changes, particularly in microbial communities, and reducing the influence of treatment-related disturbances offers immense opportunities to trace the true pathological 113 dynamics of the microbiota during the development of IBD. Thus, recent efforts in predicting 114 IBD in healthy or preclinical individuals have successfully been employed to identify 115 dedicated transcriptional [29], physiological [30], and microbial markers that are broadly 116 117 associated with disease onset in IBD [31,32].

118

119 **RESULTS**

120 Current status of the KINDRED cohort

121 As of April 2021, the Kiel KINDRED cohort included 1497 IBD patients and 1813 initially non-affected family members, belonging to a total of 1372 families. The data of all study 122 participants whose baseline questionnaires were double entered and quality-checked were 123 extracted from the database in a data freeze in March 2021, comprising 2393 individuals 124 (1321 IBD patients and 1072 non-affected relatives). The discrepancy in the total number of 125 study participants is due to the time lag between study inclusion and the return of biomaterial 126 and questionnaire data (plus quality check). The baseline characteristics of the healthy 127 participants, stratified by age, and of the IBD patients, stratified by disease subtype (CD, UC, 128 uIBD), are summarized in Table 1 and Suppl. Tables S3 & S4, respectively. 129

Available biosamples from the baseline collection were used to generate data for biomarkerdiscovery, including genome-wide genotyping (Global Screening Array (GSA), version 2.0

(Illumina), N=1725). These data are complemented by fecal 16S rRNA-based microbiome 132 profiles (N=1812), blood biomarker profiles (C-reactive protein, N=316; hemoglobin, N=49; 133 mainly IBD patients), serum antibodies (ASCA IgA, N=781; ASCA IgG, N=780; anti-GP2 134 IgA, N=781; anti-GP2 IgG, N=781), and fecal indicators of inflammation (calprotectin, 135 N=1763; occult hemoglobin/haptoglobin status, N=1760; Bristol stool score, N=882). For a 136 subset from the first and second follow-ups (N_{F1}=648, N_{F2}=539), 16S rRNA sequencing data, 137 fecal calprotectin (N_{F1} =519, N_{F2} =147), hemoglobin/haptoglobin measurements (N_{F1} =516, 138 $N_{F2}=144$), Bristol stool score ($N_{F1}=316$, $N_{F2}=255$) and blood biomarkers for inflammation 139 (Hb: NF1=203, NF2=162; CRP: NF1=179, NF2=127) were also available. Our study set 140 141 included 7 cases of IBD onset (four in the BL \rightarrow F1 group, one in the F1 \rightarrow F2 group, and 142 two in the F2 \rightarrow F3 group; see Figure 1A).

143 Distribution of physiological and clinical biomarkers of inflammation in the KINDRED 144 cohort

We detected several highly interesting patterns among the biomarkers of inflammation, but 145 our analyses focused on samples from the baseline examination because of the large number 146 of samples and biomarkers. In the baseline samples, the concentrations of the antifungal 147 antibodies anti-Saccharomyces cerevisiae antibody (ASCA) IgG and IgA decreased with age 148 149 and increased with BMI (Table 2). ASCA antibody levels were greater in CD patients than in healthy controls and UC patients (Figure 1B). Furthermore, the concentration of anti-150 glycoprotein 2 IgA and IgG (GP2), which have previously been reported to be reliable 151 biomarkers for PSC and CD [33-35], significantly differ between healthy relatives and IBD 152 patients, and are significantly associated with patient age, BMI and sex, with the 153 concentration of anti-GP2 Ig's decreasing in females and increasing in males. We detected a 154 particularly high average concentration in CD patients compared to either that in UC patients 155 or non-IBD control subjects (Table 2). The fecal calprotectin concentration, a general measure 156 157 of inflammatory processes in the gut and a metal sequestering protein, decreases with age in

IBD patients but significantly increases in CD patients, followed by UC patients (Figure 1B). 158 159 The concentration of C-reactive protein (CRP), similar to hemoglobin (Hb) levels, both measured only in diseased individuals, increased with BMI, while Hb levels in affected males 160 were significantly greater than for women with IBD (Figure S4). Stool consistency, as 161 162 expressed by the self-reported Bristol stool score (BSS), strongly and significantly increases with age. This age-related increase in BSS was particularly strong in CD patients (Figure 1B; 163 164 Table 2). This indicates that older CD patients suffer from greater bowel irritation and thus shorter intestinal passage times. At other examination time points, the associations were 165 mostly comparable to the associations in the baseline analyses, as reported in Table 2. 166

167 Genetic predisposition to IBD can be expressed by polygenic risk scores (PRS) and is 168 associated to physiological signs of inflammation

Due to the increasing number of variants associated to IBD it has become possible to quantify 169 an individual's genetic risk or genetic predisposition to CD, UC, or IBD using Polygenic Risk 170 171 Scores (PRS) [36]. On average CD- and UC-PRS were relatively disease specific as they only showed significant differences from healthy KINDRED participants in the respective patient 172 subset, with the exception of the more general IBD-PRS which was clearly increased in CD 173 174 and UC patients alike, compared to healthy control individuals (Figure 1C). Interestingly, the average UC-PRS and general IBD-PRS were significantly elevated among future onset cases, 175 while the CD-PRS showed no clear pattern. In addition to the average higher genetic risk 176 present in future onset cases, the probability of IBD onset was significantly associated with 177 UC-PRS and IBD-PRS, even though only nominally statistically significant (see Table S6, 178 Figure S6A). The genetic risk for IBD should naturally be increased in IBD patients, 179 compared to healthy individuals in general, a pattern displayed by all three PRS variants. 180 However, closely related healthy first-degree relatives (FDRs) showed no significantly 181 elevated PRS. The average genetic risk for IBD did not significantly differ among healthy 182

FDRs, more distant relatives (>1st degree relatives), and unrelated controls (Figure S7). This pattern points to a significantly stronger accumulation of risk variants in affected individuals and onset patients, even in comparison to closely related family members and a high disease specificity of the respective PRS except for the more general IBD-PRS.

In our analyses, we tested PRS-CD, PRS-UC, and PRS-IBD for associations with different biomarkers. We detected a significant positive relationship only between CD- and IBD-PRS and the levels of ASCA-IgA/IgG and, to some extent, between IBD-PRS and the levels of anti-GP2-IgA (Figure 1D, Figure S5, Table S5). However, other inflammatory markers, such as calprotectin, BSS, CRP, and Hb did not show any, or only weak associations with genetic risk scores for IBD (Figure 1D, Figure S5, Table S5).

193 Differential abundance of microbial taxa across IBD pathologies and time

Among the three time points we investigated, the fecal communities were dominated mainly 194 by members of the phylum Bacteroidetes, followed by members of Firmicutes and 195 Proteobacteria, and minor taxonomic groups (e.g. Fusobacteria, Tenericutes, Candidatus 196 Saccharibacteria; Figure 2A, Figure S8). At this high taxonomic level strong differences 197 between the main IBD pathologies are detectable, as reflected in the association of 198 199 Bacteriodetes and Firmicutes with the control individuals and the associations of Proteobacteria, Fusobacteria and Cand. Saccharibacteria with IBD, particularly CD (Figure 200 S6, Table S7). These associations are consistent over time and carry down to the ASV level 201 (see below). 202

By investigating abundance differences at the ASV level, we detected more than 750 significant differentially abundant taxa/ASVs among the main IBD pathologies (BL: 294, F1: 150, F2: 193, combined: 536; Figure 2B). At the baseline time point we detected taxa belonging to the *Enterobacteriaceae* (Gammaproteobacteria), such as *Haemophilus*,

Escherichia/Shigella, Raoultella, and Klebsiella, which were strongly overabundant in IBD 207 patients (Figure 2C). Particularly in the fecal community of CD patients we observed a high 208 abundance of Klebsiella and other Enterobacteriaceae, which persisted over time (see Figure 209 2C, S9, S10). In the phylum Firmicutes we found various associations with different IBD 210 Members of Veillonella, Megasphaera, Dialister, Enterococcus, 211 pathologies. and Granulicatella were more abundant in CD and UC patients alike. In contrast, members of the 212 Ruminococcaceae (e.g. Clostridium IV, Oscillibacter, Faecalibacterium) are consistently 213 overrepresented in healthy individuals. Ervsipelotrichaceae is more abundant in IBD patients 214 and is frequently associated with UC. Members of the Bacteroidetes, with the exception of 215 216 some *Bacteroides sp.* are consistently more abundant in healthy individuals, *e.g. Alistipes*, 217 Prevotella, Alloprevotella, Parabacteroides, and Bacteroides (see Figure 2C, S9, S10).

Interestingly IBD-associated taxa belonging to Veillonella, Dialister and Granulicatella 218 (Firmicutes), but also Haemophilus, Klebsiella (Proteobacteria), and Rothia (Actinobacteria) 219 are prominent indicators of oral colonization of the intestinal microbiome. Similarly, a rarely 220 221 described disease associated taxon, Cand. Saccharibacteria [37] are commonly found in the oral microbiome. Fusobacteria (i.e. F. nucleatum), which are generally associated with the 222 development of colorectal cancers, were found to be overabundant in CD patients and could 223 also be replicated in external cohorts (see Table S8-S11). The majority of associations, such 224 as the associations of Veillonella, or members of Clostridium XIVa clostridioforme), 225 Clostridium XVIII ramosum), and Clostridium sensu stricto groups with IBD, or the higher 226 abundances of ASVs belonging to Alistipes and uncl. Clostridiales in healthy individuals, can 227 be consistently detected in external cohorts, although some incongruities exist between 228 229 cohorts (e.g. Oscillibacter ASVs in KINDRED-Contr./SIC-IBD patients).

230 Various taxa showed significant correlations with clinical indicators of intestinal231 inflammation and genetic risk scores. Indicators of oralization correlate with physiological

signs of inflammation (e.g. R. mucilaginosa-BSS \downarrow , Cand. Saccharibacter-calprotectin \uparrow , 232 *Klebsiella uncl.*- BSS ↑, *F. nucleatum*-calprotectin ↑, *Dialister invisus*-BSS↓ & anti-GP2 233 IgA/IgG \downarrow , *Veillonella uncl.*-IBD-PRS \uparrow). Interestingly, most Firmicutes correlated very 234 consistently and almost entirely positively with the Bristol stool score (BSS) under IBD 235 conditions (IBD, CD, UC), while members of the Bacteroidetes correlated very consistently 236 negatively with BSS, encompassing pathobionts and commonly probiotic taxa (see Figure 2C, 237 Table S12). This pattern was also present in healthy individuals, but did not reach 238 significance. When we focused on the association of bacteria with genetic risk for IBD, we 239 found that most Bacteroidetes (e.g. Alistipes) were correlated with decreasing genetic risk for 240 CD, UC, and IBD, with the exception of Bacteroides fragillis (Figure S11, Table S13). 241 Interestingly, Barnesiella uncl., a common butyrate producer, correlated positively with 242 genetic CD risk in healthy individuals, but correlated negatively with genetic CD risk in 243 diseased individuals. In general, correlations with clinical parameters and genetic risk were 244 most frequent in IBD patients, especially in CD patients, while almost no significant 245 correlations were detected in UC patients. Different IBD associated Proteobacteria, 246 specifically members of Enterobacteriaceae are strongly associated with increased ASCA 247 IgG/IgA levels and calprotectin levels, as well as decreased gut transit time (increased BSS; 248 249 e.g. ASV 99 Escherichia/Shigella coli) only in IBD/CD patients, similar to the findings for 250 the IBD/CD associated Firmicutes *Clostridium XIVa clostridioforme* (ASV-103). Moreover, the Enterobacteriaceae (e.g. ASV-42-Enterobacteriaceae uncl., ASV-165-Citrobacter uncl.), 251 252 as well as members of the *Clostridium XIVa* strongly correlated with increasing genetic risk for IBD, and more precisely CD in the patient cohorts (Figure 2C & Figure S11; Table S12). 253 Several Firmicutes SCFA producers correlate with decreasing ASCA IgG/IgA levels and IBD 254 risk in healthy and diseased individuals (e.g. ASV 71 Faecalibacterium uncl.), while the 255 abundances of others correlate with elevated levels of genetic risk, particularly in diseased 256 individuals (e.g. Blautia, Ruminococcacea uncl.). Overall, we observed consistent 257

associations of ASVs to genetic risk for IBD and different clinical markers for IBD, with only
minor associations in UC patients or with genetic risk for UC.

260 Alpha diversity patterns associated with IBD pathology, clinical characteristics, and 261 microbial dysbiosis

A critical characteristic of ecosystems is their complexity, which can be informative for 262 263 assessing the community state, productivity or stability and can be based on, e.g. the number of community members, their distribution, or their phylogenetic relationships. Overall, we 264 identified an extensive loss of species diversity in IBD patients with respect to species 265 266 richness (Figure 2D), complexity or phylogenetic relatedness of community members (NTI<0, NRI<0) (Figure S12, Table 3). Individuals suffering from CD show a significantly 267 greater loss of diversity than UC patients based on richness and complexity but not at the 268 phylogenetic level. Onset cases only showed a slight but insignificant reduction in diversity 269 (less richness, less complexity, less phylogenetic dispersion). 270

271 Based on the differential abundance patterns we derived two indices of host health based on the bacterial abundance and distribution, namely, the Microbial Dysbiosis index (MD-index) 272 as introduced by Gevers et al. (2014) and the more generalized GMHI (general microbiome 273 274 health index) as developed by Gupta et al. (2020) [38,39]. Focusing on the MD-index we can observe a clearly negative correlation of alpha diversity with community dysbiosis at any 275 level, further implying an accelerated loss of taxon diversity with increasing dysbiosis 276 (breakpoint at MD=0.615, Figure 2D, Table S13). The phylogenetic composition changes to 277 become more random with increasing dysbiosis but shows a less severe pattern than species 278 279 richness or abundance distribution (Figure S12, Table S13). Across all time points we can identified a trend of strongly decreasing diversity in UC and CD patients with increasing 280 dysbiosis, while healthy controls showed a far slower decline of diversity under increasing 281 dysbiosis, particularly in the taxon-based indices (Table S14). The correlations of different 282

alpha diversity metrics with the GMHI showed comparable but weaker relationships as
observed with the MD-index. Alpha diversity metrics are further negatively (Chao1, Shannon
H) and positively (NRI, NTI) correlated with physiological signs of inflammation, such as
ASCA-IgA/IgG, calprotectin, and BSS, particularly in IBD patients, which translates to more
severe signs of inflammation at a lower community diversity in diseased individuals (CD, UC,
uIBD; Figure 2G, Table S15).

289 Community differences between IBD pathologies are associated with clinical-, 290 anthropometric- characteristics, patterns of community dysbiosis, and genetic risk

By investigating community similarities at different levels, we revealed various patterns of 291 health-associated, anthropometric, and lifestyle related community differences. In particular, 292 IBD pathology showed a strong association with community differences, with the strongest 293 separation between microbial communities originating from healthy individuals and those 294 originating from CD patients (Figure 3A; Table S16). In this context, we observed a strong 295 296 association of the taxonomic community composition with the MD-index and to a lesser extent with GMHI (Table S16). This gradient of dysbiosis parallels the community 297 differentiation between healthy and diseased individuals, but also recapitulates significant 298 299 gradients of physiological markers for inflammation such as BSS, ASCA IgA/IgG levels, and calprotectin levels in the communities (see Figure 3A, 3B, 3J; Figure S13, S14; Table S17 & 300 Table S18). We also detected significant, yet weak correlations between taxonomic 301 community composition and polygenic risk scores, which were very weak for UC associated 302 genetic risk and strongest for CD and general IBD risk at the taxonomic- (Figure S7D) and 303 functional levels (Figure S7E) and followed the direction of the dysbiosis gradient. Similarly, 304 the cumulative genetic risk for CD and general IBD positively correlated with the MD-index, 305 while UC-PRS displayed no significant correlation, similar to GMHI (Figure S5B & S5C). 306

Furthermore, onset cases were mostly distributed around the mean of the community 307 308 compositional distribution and dysbiosis gradient, and thus did not represent community outliers (Figure 3C, Figure S13 & S14). The MD-index (and GMHI) strongly distinguished 309 IBD and non-IBD individuals and corresponded with the clustering of microbial communities 310 311 with respect to IBD pathology, even if applied to external patient cohorts (Sweden, Malta) (Figure 3E-3H, Figure S14G). The MD-index is most strongly elevated in CD patients and 312 further distinguished CD patients (particularly treatment-naïve) from healthy controls in the 313 Maltese cohort (Figure 3H). GMHI displayed on average a more consistent decrease in 314 diseased individuals across all cohorts, and further distinguished UC patients from healthy 315 316 controls (Figure S14H). These "universal" disease patterns are also reflected in the sample 317 clustering by IBD condition, irrespective of cohort origin (conditional dbRDA (conditioned by geographic origin): $F_{4,3308}$ =4.0406, P<0.0001, adj. R²=0.0037) and through the significantly 318 elevated taxonomic and functional community variability in IBD patients compared to healthy 319 controls within (Figure 3D, Figure S14H & S15, Table S20) and across cohorts (Figure 3G & 320 S14H). 321

322 Both dysbiosis scores corresponded closely with several physiological signs of inflammation, such as the reactivity to fungal antigens as expressed via ASCA IgG or IgA titers, or related 323 324 immunological markers, like anti-GP2 IgG and IgA levels (Figure 3I & 3J, Figure S16, Table S18). ASCA antibody levels increased most strongly in CD patients with increasing MD score 325 (decreasing GMHI). In contrast, anti-GP2 IgA/IgG levels positively correlate with MD but 326 appear to show a slight overall increase and higher average MD levels in CD and UC patients, 327 as expected. Overall, the relationship of GMHI and MD-index with ASCA or anti-GP2 328 329 antibody levels were comparable (Table S18). The GMHI and MD-index displayed strong associations with the BSS, with lower stool consistency in IBD patients and increasing 330 dysbiosis (MD \uparrow , GMHI \downarrow) (Figure 3I). The MD-index was strongly associated with 331

increasing BMI and calprotectin levels, which were on average higher in CD and UC patients than in healthy controls (Figure 3I, Figure 1B). The concentrations of serum CRP- and Hb levels, which were only assessed in diseased individuals, were not significantly associated with microbial dysbiosis metrics (Figure S16). The practitioner's overall assessment of disease severity in IBD patients only (1-no/4-severe inflammation), revealed a strong positive association with MD, while GMHI was not significantly correlated.

When we investigated dysbiosis patterns among FDRs, we observed that the MD and GMHI in affected individuals were greater or lower, respectively, than those in healthy family members. However, healthy FDRs of IBD patients, generally related, or unrelated healthy individuals, did not show a greater degree of dysbiosis. However, the MD-index was weakly associated with an increased probability of IBD onset (DF=1,1735, *Z*=-2.0685, *P*(*Z*)=0.0386, N_{onset} =7/1815; DF=1,726, *Z*=-1.2579, *P*(*Z*)=0.2084, N_{onset} =7/794; binomial GLM), while the GMHI showed no significant association with IBD onset.

345 IBD pathologies were consistently the most influential health conditions for the taxonomic and functional differences of the microbial communities (Figure 3J & Figure 4D, Table S21). 346 The most pronounced differences were between the healthy controls and CD patients, 347 348 followed by the differences between healthy controls and UC patients, while functional and taxonomic differences between UC- and CD patients persist (see Table S16, Table S21). 349 Together with the presence of a stoma/artificial bowel outlet (colostomy, ileostomy, 350 permanent/temporary stoma), other pathologies that influence the anatomic structure or gut 351 transition time, such as obstipation, diarrhea, and intestinal stenosis strongly influence the 352 taxonomic and functional composition of the microbial communities (Figure 3J). Thus, 353 chronic and acute diseases, which influence passage time, have a significant impact on the 354 taxonomic and functional composition of the intestinal microbiome. This pattern remained 355

consistent even after excluding potential confounding effects such as age, BMI, sex, and IBD
pathology (see Table S21).

In addition to the impact of different pathologies, most importantly IBD, we observed a 358 359 significant impact of various pharmaceutical treatments on microbial communities. Interestingly, antibiotic treatments between 6 weeks and one year prior had significant but not 360 prominent effects as reported by [40]. However, the most influential were drugs that modify 361 the fecal passage time (e.g. Loperamide, surfactants), further pronouncing the strong and 362 consistent association of BSS with community composition. In particular, these 363 pharmaceuticals remained influential after correcting for IBD condition, age, BMI, and sex 364 (Figure 3J, Table S22) and associated with higher levels of BSS (W=24756, $P=3.3910\times10^{-9}$, 365 Wilcoxon-test). 366

Investigating the impact of macro and micronutrient intake on the microbiota revealed a very 367 interesting parallel distribution of F20:4 (Eicosatetraenoic acid/Arachidonic acid) and 368 369 MD/GMHI indices with the microbial community composition (Figure 3J, Figure S13G-I), which was the only nutrient whose intake associated with an increasing dysbiosis signal in the 370 microbial community, in direct correlation (Figures S14J; Table S23), and consistent in 371 follow-up time points (see Figure 3J & S13G-I; Table S23). This eicosanoid precursor can be 372 a potent, immunologically active molecule [41] and its uptake at baseline was weakly 373 correlated to MD (ρ =0.0486, P=0.0772, Spearman correlation), BMI (ρ =0.1278, 374 $P=4.7168 \times 10^{-6}$), ASCA IgG ($\rho=0.0647$, P=0.0881), and calprotectin ($\rho=0.0514$, P=0.0648). 375 376 Increasingly dysbiotic communities were further correlated to increasing consumption of glycogen, various amino acids and general protein uptake (ZE), which can be interpreted as 377 elevated uptake of animal products (Figures S14J), which paralleled the gradients of 378 inflammatory markers (e.g. calprotectin; see Figures S13D-F & Figures S13G-I). In contrast, 379 the increased uptake of various vitamins and trace minerals, as well as long-chain 380

carbohydrates (e.g. ZB-Fiber) significantly coincided with a less inflammatory/disturbed
community structure (GMHI and MD) and were associated with reduced physiological signs
of inflammation, potentially via SCFA production [42]. The functional community
composition was only associated with vitamin B derivatives and trace mineral consumption
(see Figure 4D & Figure S17G-I; Table S23).

386 Uncharacteristic community clusters (DMM) are associated with dysbiosis and clinical 387 signs of inflammation

Unsupervised community clustering revealed three community clusters, which do not fully 388 correspond to previous reports [43], but share common indicators reported in the literature 389 (Figure 4A). Cluster-1 is characterized by a high abundance of Prevotella and 390 Ruminococcaceae (Prevotella: P_{FDR} =1.1162×10⁻²⁶; Ruminococcus: P_{FDR} =2.1846×10⁻⁵⁹; 391 Kruskal test), while cluster-2 shows a high abundance of e.g. Bacteroides and 392 Faecalibacterium (Bacteroides: P_{FDR} =1.4604×10⁻¹⁷; Faecalibacterium: P_{FDR} =1.5310×10⁻⁸⁴; 393 Kruskal test). In contrast, individuals in Cluster-3 showed a greater propensity for 394 inflammation as indicated by the elevated MD-index ($P \le 2.2 \times 10^{-16}$; Kruskal test, Figure 4B & 395 4C) and community variability (Figure 4D), as well as increased levels of physiological 396 inflammation markers such as ASCA-IgG/IgA, and increased stool moistness/softness (Figure 397 S18A). This cluster further showed a higher abundance of Enterobacteriaceae (e.g. 398 *Escherichia/Shigella*: P_{FDR} =4.0936×10⁻⁶¹; Kruskal test), which is unconventional for so-called 399 "enterotypes". However, this community type has been reported before and appears to 400 correspond to a dysbiotic community state, positioned outside the standard community states 401 reported sofar [44–46]. In addition, we detected a significantly greater level of genetic risk for 402 CD ($F_{2,1665}$ =12.5869, P=3.7541×10⁻⁶; LM) and general IBD ($F_{2,1665}$ =4.3156, P=0.0135; LM) 403 among individuals in this unconventional community cluster, but not for UC risk 404

405 ($F_{2,1665}$ =0.1712, P=0.8427; Figure S18B), indicating the strong effect of IBD and a broad 406 genetic disease risk on community composition.

407 Imputed community functions reveal the importance of amino acid related pathways and 408 bacterial surface structures in health and disease

On average, communities differ more strongly between IBD pathologies based on the imputed 409 functions compared to taxonomic differences, particularly regarding the difference between 410 healthy controls and CD patients (Table S16). The ranking of single associations of 411 pathologies, physiological parameters, and pharmaceutical treatments with functional 412 413 community differences overlaps with the taxon-based analyses, although fewer associations can be detected (Figure 4E & 4F, Figure S17, Table S17, S21, S22, S23). Additionally, 414 physiological signs of inflammation, such as ASCA IgA/IgG or decreasing stool consistency 415 parallel the dysbiosis gradient in the functional composition (Figure 4E, Figure S17, Figure 416 S17D; Table S16, S17). The MD-index and GMHI explained a greater percentage of 417 community variation at the functional level (see Figure 4A, Figure S17M; Table S16), while 418 functional community differences were only weakly correlated with the genetic risk scores for 419 CD (*P*<0.05; Figure S6E). 420

At the level of single functions, we detected various differentially abundant KEGG 421 Orthologous Groups (BL: N_{total}=5071, F1: N_{total}=4347; F2: N_{total}=4402). By investigating 422 systematic changes in functional abundances via Gene Set Enrichment Analysis [47], we 423 identified various highly persistent functional differences between disease states, which were 424 425 further supported in the external cohorts (Table S24). Various metabolic pathways involved in 426 the metabolism and biosynthesis of amino acids, ranging from general Biosynthesis of amino acids, to Phenylalanine, tyrosine and tryptophan biosynthesis, among others, are consistently 427 enriched in healthy individuals or rarely in UC patients compared to CD patients. Other amino 428 429 acid-related pathways were similarly enriched in healthy individuals (Arginine biosynthesis;

Alanine, aspartate and glutamate metabolism; Valine, leucine and isoleucine biosynthesis; 430 Lysine biosynthesis; see Figure 4E; Table S24). Basic metabolic functions and cell growth 431 were more strongly represented in healthy controls and were repeated among the other cohorts 432 in a similar direction (e.g. Citrate cycle (TCA cycle), Oxidative phosphorylation; Figure 4H, 433 Figure S19-S22; Table S24), as were pathways involved in bacterial motility and biofilm 434 formation, which were enriched in healthy individuals (Bacterial chemotaxis, Flagellar 435 assembly, Biofilm formation - Pseudomonas aeruginosa). Oxidative phosphorylation also 436 entails anaerobic electron transfer reactions (anaerobic respiration) that reduce other electron 437 acceptors than oxygen for ATP generation (e.g. nitrate, sulfate, fumarate), as performed by 438 439 various intestinal bacteria (e.g. Desulfovibrio). In contrast, functions related to carbohydrate degradation (e.g. ABC transporters, Phosphotransferase system (PTS), Fructose and mannose 440 metabolism, Galactose metabolism) were very consistently enriched in IBD-associated 441 communities and may, in combination with changing SCFA levels (F1 & F2: Propanoate 442 metabolism and Butanoate metabolism), contribute to mucosal degradation. Bacterial traits 443 that are central to the generation and integration of immune modulatory factors of gram-444 negative (Lipopolysaccharide biosynthesis) and gram-positive bacteria (Teichoic acid 445 biosynthesis, Peptidoglycan biosynthesis) were also consistently enriched among IBD patients 446 447 (Figure S19-S22; Table S24).

448 Network analyses show systemic and transferrable patterns of community disturbance, and 449 high disease dependent taxon centrality in community networks

To analyze the microbial community as a whole, we constructed co-abundance networks to identify important taxa and patterns in the fecal microbial communities that may be central for community and host homeostasis (Figure 5A). Across networks (split by time point, or by time point and pathology), we observed significant differences in the composition and topography at the network level between IBD pathologies and healthy community networks in

the KINDRED cohort (control vs. IBD: $F_{1,7}=2.4873$, P=0.0947, $R^2=0.2622$, adj. $R^2=0.1568$; 455 456 see Figure 5B).. This also held true when external IBD cohorts were included (Control vs. IBD: F_{1,12}=2.1301, P=0.0604, R²=0.1507, adj. R²=0.0800, Control vs. IBD (incl. general IBD) 457 networks): $F_{1,18}=2.4144$, P=0.0412, $R^2=0.1183$, adj. $R^2=0.0693$, Graphlet distance; Figure 5C 458 & Figure S27A). Furthermore, we observed signs of network/community contraction in IBD 459 communities in the KINDRED cohort, as implied by the increasing network density and 460 radius in diseased community networks, which remained consistent when we included 461 networks derived from healthy and diseased external cohorts (Figure S27B). In addition, 462 "natural connectivity" is increased in IBD communities, which strongly suggests a greater 463 464 resistance to disturbances or stochastic changes by those communities. A higher "natural connectivity" after disease manifestation implies more densely connected networks with 465 fewer bottlenecks, and pronounced community structure, which tend to possess a greater 466 467 robustness against random fluctuations and community decay [48,49].

At the single taxon level/node level (Figure 5A, Figure S23-S26), we observed various 468 469 pathogenic and IBD associated groups, consisting mainly of Clostridium XVIII ramosum 470 (Erysipelotrichaceae: ASV 193) and Clostridium XIVa clostridioforme/spec. (e.g. ASV 103, ASV 171), as well as various members of the oral community (e.g. Veillonella, Rothia, Cand. 471 472 Saccharibacteria, Fusobacterium) and Enterobacteriaceae (e.g. Klebsiella), to be consistently central across time points (particularly in diseased networks) and characteristically abundant 473 in IBD patients. Similarly Flavonifractor plautii (ASV 93, Ruminococcaceae) or the 474 Actinobacterium Eggerthella lenta (ASV 713), are elevated as well in IBD, highly central, 475 and known for pro-inflammatory characteristics [50-54] (Figure S23-S26, Table S25). In 476 477 contrast, ASVs belonging to Alistipes (i.e. A. putredinis, Alistipes spec., A. shahii) are highly central and consistently abundant in control individuals across time points and external 478 cohorts, like other SCFA producing bacteria (e.g. Porphyromonadaceae: Barnesiella, 479

480 Odoribacter, Parabacteroides spec.; Lachnospiracea: Clostridium XlVb uncl.;
481 Ruminococcacea (Clostridial cluster IV, Ruminococcus; Figure 5A, Figure S23-S26, Table
482 S25). However, through the nature of network construction through statistical means,
483 centralities, and key-stone status may vary [55,56].

484 Heritability of microbial taxa

Using a mixed model framework, we investigated the heritability of single ASVs using 485 pedigree relationships in the cohort. Most of these associations were driven not only by host 486 kinship or family conditions, but also by environmental/ anthropometric/ lifestyle 487 488 characteristics (age, sex, BMI, and IBD status). At the ASV level, the taxa showing the highest heritability estimates were mainly members of the *Bacteroides*, while particularly 489 Bacteroides uniformis (ASV-6, $h^2_{null}=0.4723$) and Paraprevotella uncl. (ASV 84, 490 $h_{full}^2=0.4783$) had the highest heritability estimates (Table S26). Most taxa were impacted by 491 environmental influences in addition to the apparent kinship effect/familiar transmission 492 $(h_{mull}^2 < h_{full}^2)$; Figure 5D, Figure S28A; Table S26). Interestingly, potential probiotic bacteria 493 abundant in healthy individuals, or mutualistic taxa (not associated to IBD) displayed high 494 495 heritability (e.g. Parabacteroides uncl., Feacalibacteria uncl., A. muciniphila, B. 496 thetaiotaomicron, Alistipes uncl.). Akkermansia muciniphila displayed a lower impact of environmental/anthropogenic variables $(h_{null}^2 > h_{full}^2)$ on the inheritance patterns, and displayed 497 a better fit solely by relatedness (h^2_{null} =0.2573, Figure 5D, Figure S28A), similar to other 498 highly heritable taxa, such as the ubiquitous human gut commensal Bacteroides uniformis 499 [57] (Table S26). However, among the top 25% percent of the most heritable ASVs, we 500 observed disease-associated taxa, mainly belonging to the Proteobacteria such as e.g. 501 Escherichia/Shigella (ASV-5, ASV-10) or the typical oral Dialister invisus (ASV-17, 502 Firmicutes), which were more abundant in IBD patients. The community wide dysbiosis 503 indices (MD-index and GMHI), showed relatively strong heritability as well, which implies a 504

genetic influence or intra-family transmission of dysbiosis. GMHI was within the boundaries 505 of ASV based estimates in our cohort ($h_{full}^2=0.1401$), while the heritability of the MD-index 506 was clearly lower (h_{full}^2 =0.0813) and distinctly lower than estimates reported by Turpin *et al.* 507 2016 (h^2 =0.2728) for the MD-index or the heritability estimates for IBD itself (CD: 0.25-0.42, 508 UC: 0.04-0.15) [58,59]. Overall, heritability of the communities appears to be disturbed in 509 cases of IBD, as we observed a reduced correlation of community composition and genetic 510 distance (kinship, IBS distance) in IBD cases compared to healthy individuals (Figure S28B), 511 although overall correlations were still significant (kinship- r=0.4406, m²12=0.8059, 512 *P*=0.0009, IBS- *r*=0.4272, m²12=0.8175, *P*=0.0009; Procrustes test). 513

514

515 DISCUSSION

In this cohort study we investigated the state and evolution of IBD by combining taxonomic 516 and functional microbial data from several successive time points with extensive 517 518 anthropometric, medical, nutritional, and social information. Genome-wide association studies focusing on IBD revealed various genetic risk loci for IBD, which may contribute to 519 immune dysregulation, antimicrobial immune reactions, and changes in host-microbiome 520 homeostasis [60,17]. Various studies have investigated the interplay between microbes, 521 metabolites, and host characteristics. These analyses revealed distinct physiological and 522 microbial manifestations of the different IBD pathologies, which are reflected in external 523 disease cohorts. The unsupervised community clustering (DMM community cluster 3) and 524 significant differences of IBD patients across cohorts, highlight the severity of community 525 526 turnover during IBD [46] and a strong signal of dysbiosis which may even warrant one or multiple distinct community states. Similarly, the strong differentiation of IBD-specific 527 networks from healthy ones points to large changes in community dynamics after disease 528 manifestation. These changes potentially result in a resilient or resistant community state as 529

implied by the more connected, denser, and robust networks after IBD manifestation (radius, 530 531 density, natural connectivity) even across cohorts [49]. The consistently observed increased community variability in diseased individuals is a probable result of community transitions. 532 This phenomenon, the so called "Anna Karenina pattern", describes a pattern in which 533 microbial communities of dysbiotic/diseased individuals are more different from each other 534 than communities of healthy individuals are among each other. This phenomenon may be 535 attributed to a loss of regulation or strongly individualized stochastic effects on community 536 composition after IBD development [61] and has been detected in other IBD studies [25,62-537 64]. In summary, different community characteristics, such as increasing interindividual 538 539 variability, greater community density/connectivity, and large compositional changes after IBD manifestation, point toward large and to some extend universal community 540 transformations in IBD development. 541

542 Physiological and genetic markers of inflammation are strongly disease specific, associated 543 to the microbiome, and associate to disease onset

544 The two main IBD pathologies, CD and UC, are physiologically, anatomically, and microbiologically quite distinct. We identified disease specific patterns in several 545 physiological markers of IBD. In particular, anti-fungal ASCA IgG and IgA have strong 546 associations to CD and IBD in general. ASCA Ig levels were not reported to be associated to 547 high risk genetic markers of CD (CARD15/NOD2), but that its effect sizes might be 548 genetically determined [65]. Thus, ASCA levels themselves are not genetically determined. 549 550 but rather their responsiveness, which reflects the strngth of inflammatory reactions to environmental antigens, potentially also of bacterial origin. In contrast we showed a 551 significant association with polygenic risk scores for IBD, particularly CD, which was not yet 552 shown before (Lee et al., 2021), and might originate from the wider array of cumulative 553

genetic risk factors known since the investigation by Halfvarson et al., 2005. This strong
relationship of the PRS was not present for other physiological IBD biomarkers in this study.

556 Similar to ASCA Ig levels, anti-glycoprotein 2 antibodies (GP2) have been described as 557 strong biomarkers for IBD [33,35], while fecal calprotectin represents a biomarker of general 558 intestinal inflammation. All displayed strong disease specific differences and are strongly 559 correlated with bacterial community characteristics such as composition, diversity, dysbiosis 560 indeces, but far weaker associated to the genetic risk scores for IBD. Bacterial taxa that 551 associated to ASCA levels overlap only in parts with a recent study in UC patients at the 552 family level (*e.g. Ruminococcaceae*) [66].

Decreased stool consistency, an indicator of reduced intestinal transit time, elevated fecal 563 water content and eventually diarrhea, are hallmarks of IBD pathology. Although not 564 associated with genetic risk for IBD, stool consistency decreases dramatically with increasing 565 dysbiosis, diversity, and community composition. Recently Vandeputte et al. showed the 566 567 effects of fecal passage time on community patterns in a Belgian cohort, surpassing dietary and disease related signals [67,68]. We found similar patterns, with increasing passage time 568 (lower BSS) associated with increasing populations of Bacteroidetes and decreasing 569 570 abundances of Firmicutes members. These patterns have mostly a similar orientation, but are significantly exaggerated in IBD patients, which implies a greater impact of bacteria on 571 passage time/stool consistency or a greater impact of passage time on the bacterial community 572 under intestinal inflammation. In line with the centrality of stool consistency and transit time 573 574 for community composition, we observed a strong gradient of community composition and IBD associated dysbiosis with decreasing transit time. Similarly, among the most influential 575 pharmaceutical treatments in the cohort are anti-diarrhea drugs, and the most influential 576 medical conditions in addition to IBD are conditions affecting fecal flow (stoma, obstipation, 577 diarrhea, stenoses, etc.). Changes in transit time can change the taxonomic and functional 578

579 composition-, bidirectionally interact with the microbiota, and alter the metabolite 580 composition by transitioning from saccharolytic to proteolytic metabolism [69,70].

We determined a clear connection between the genetic risk of IBD development, particularly 581 582 CD and general IBD, and the microbial community composition or level of dysbiosis. This finding emphasizes the potential connection between genetic risk factors such as e.g. FUT2 or 583 NOD2 [60,71] and their combined influence on the microbial community, potentially leading 584 585 to dysbiotic community dynamics in interaction with environmental factors. Polygenic risk scores integrate the abundance and penetrance of known risk variants for diseases such as 586 IBD into a single genome-wide risk to develop the disease. Although PRS effectively capture 587 588 established IBD variants, these scores may not account for yet unidentified genetic factors and were mainly derived from cohorts of predominantly European ancestry, thus missing out 589 population specific variants [24]. However, in this cohort genetic risk for general IBD and CD 590 591 showed stable and repeated connections to microbial- and physiological indicators of IBD and were derived and applied in a central European cohort. The relatively weak association of 592 593 UC-PRS with microbial community characteristics, in contrast points to a reduced importance 594 of the host-microbe interactions and/or lower density and penetrance of associated risk variants in UC [72]. In alignment with this, UC patients displayed comparatively weak and 595 596 fewer associations with the microbiome, as seen before [64]. However, the associations that were detected are mostly consistent with other studies [66,73]. Naturally, PRS for IBDs are 597 higher in IBD cases than in controls, however the clear and significantly elevated risk levels 598 and the weak, albeit significant, increase in the probability of developing IBD with a higher 599 PRS emphazises the potential of these scores to stratify individuals at risk and underscores the 600 601 close interaction between genetic risk and potential environmental triggers such as the microbiome in IBD development [17]. Barnesiella sp., a common mucosa-associated butyrate 602 producer, showed a positive association with CD risk in healthy individuals but was 603

negatively associated with CD risk in diseased individuals. A recent study revealed that this 604 605 taxon is associated with a TLR4 modulating variant (*biliverdin reductase A, BLVRA*), which increases the risk for CD, but may dampen inflammation in a diseased state through SCFA 606 production [74–76]. In contrast, we detected a reversal of this pattern in the commonly 607 "probiotic" *Bacteroides fragillis* [77], which displayed a positive association with CD-PRS in 608 IBD and CD patients. PRS also encompass important IBD-associated genes/risk variants for 609 autophagy (e.g. ATG16L1, NOD2), which are unable to sense the anti-inflammatory signals of 610 this taxon and may thus result in a proinflammatory cytokine bias through this taxon [78]. 611

Broad genetic patterns, as determined by kinship, influenced the taxonomic and functional 612 613 composition of the bacterial communities [79]. Social distance as well as broad relatedness have been described in detail to allow for bacterial transfer [80,81] and the transfer of 614 potential phenotypes. Thus, horizontal and vertical intrafamily transmission [80], may add to 615 the continuation and transfer of inflammation and dysbiosis as experimentally trackable in 616 mouse experiments [82,83]. Interestingly the ubiquitous human gut commensal *Bacteroides* 617 618 uniformis [57] among other Bacteroides species shows a strong association with host genetic 619 variation as has been described elsewhere for humans and mice [84,76]. Although mainly commensals, which are associated to long chain carbohydrate degradation, this capability of 620 621 *Bacteroides* may also drive pathogenic patterns in susceptible environments/hosts, due to the weakening of the mucosal barrier [85,86]. Thus, the varying genetic background of the host 622 623 and strain/species specifc functional variation may explain the varying association of Bacteroides species to IBD, particularly in light of their relatively stable host-genetic 624 associations [76]. However, in contrast to our study, the heritability of Bacteroidetes in 625 626 general and Bacteroides in particular were shown to be low in twin studies [79], but were on a 627 similar level with recent studies which used more complex kinships [87]. Another mucolytic species, Akkermansia muciniphila, was highly heritable in other studies, as well [79,87], and 628

has often been associated with weight loss and metabolic health. Here we showed a clear 629 association with non-IBD individuals, even though its role in IBD can be ambiguous [88,89]. 630 The majority of heritable taxa belong to Firmicutes (149 ASVs vs. 96 ASVs other); however, 631 highly heritable Christensenellaceae were not detected, potentially due to their low 632 abundance/prevalence in the cohort [81,79,90]. Overall, the potential inheritance patterns we 633 detected strongly resemble patterns of shared communities in mother-offspring comparisons, 634 thus potentially highlighting the dominant matrilineal influence of these analyses [80]], 635 although cohabitation could not be completely disentangled from family membership due to 636 data restrictions. In addition we detected a general correspondence between differences of 637 638 community composition and genetic distance, highlighting a community wide influence of 639 genetics and heritability. This pattern appears to be disturbed among IBD patients, potentially due to the overwhelming effect of disease and related factors on the microbial communities 640 which masks the broad genetic effects we detected. 641

642 Oralization of the intestinal community and blooming of Enterobactericeae are common 643 IBD characteristics across cohorts

A strong microbial pattern in IBD, particularly for CD, arises from the highly consistent 644 association of oral bacteria with the disease. Various taxa across different phyla with a typical 645 oral origin show clear associations with IBD (Cand. Saccharibacteria, Rothia, Veillonella, 646 Dialister, Fusobacteria, Klebsiella) and highlighted a potential loss of colonization resistance 647 648 of the community or detrimental physiological alterations. Cand. Saccharibacteria (formerly 649 TM7) is a rarely described obligate bacterial epibiont involved in IBD-related microbial 650 dysbiosis and oralization [37], but appeared very consistently in the investigated cohorts [64]. Additionally, R. muciliginosa is an oral taxon with a clear association with IBD, which 651 interestingly closely associates with Cand. Saccharibacteria (Figure S29). It may thus 652 represent a potential host for this taxon in the intestinal environment, as it until recently 653

belonged to the same family as its oral hosts (Actinomycetaceae) [91]. Alternatively, this 654 655 group may represent an independent TM7 group adapted to the intestinal environment, as observed in the ruminant TM7-G3 cluster [92] with its own host species. F. nucleatum and its 656 cell components have been proposed as causal triggers of inflammation in e.g. rheumatoid 657 arthritis [93] or even IBD [94], and have been implicated in the development of colorectal 658 cancer [95]. Recent studies also displayed several overlapping, mostly oral bacteria associated 659 660 to UC, such as Veillonella dispar, Megasphaera micronuciformis, Haemophilus parainfluenzae, and other Enterobacteriaceae [96] and a reduction of these ectopically 661 colonizing oral bacteria can promote remission in IBD patients [66]. Furthermore, oralization 662 663 of the microbiome and oral health itself are strongly associated to IBD development, risk, and 664 severity [97,98].

IBD 665 However. the most consistent pattern of association was observed for *Enterobacteriaceae*, such as potentially oral *Klebsiella sp.*, which are highly proinflammatory 666 and often associated with UC and PSC, although we mainly detected stable associations with 667 668 CD and IBD [97]. In addition, Escherichia/Shigella show clear and valid pathogenic or proinflammatory characteristics [38,99] and appear to characterize a distinct, potentially 669 dysbiotic community type (DMM cluster-3), as previously proposed [44,45]. Various 670 671 Enterobacteriaceae, are known to elicit strong immunological reactions and are associated with the development of IBD at various levels ranging from ecological (facilitation [100]) to 672 metabolic [101] interactions that allow these taxa to benefit from inflammatory processes 673 [102]. However, some members of the Escherichia/Shigella have been shown to be beneficial 674 for the immunological development early in life [103] or carry beneficial characteristics 675 676 [104]. Differentially abundant taxa, particularly oral taxa (Fusobacterium, Dialister, *Veillonella*) and the abundance patterns of *Enterobacteriaceae* correspond well with a recent 677

678 large meta-analysis of IBD studies, as do abundances of potentially beneficial taxa (*e.g.*679 *Faecalibacterium*, *Ruminococcaceae*, *Alistipes*) [105].

680 Amino acid metabolism and flagellar functions associate strongly with healthy individuals

Interestingly, one of the most enriched functions differing between healthy and diseased 681 individuals is Aminobenzoate Metabolism. Anthranilate or 2-Aminobenzoic acid is a key 682 metabolite of bacterial aromatic compound degradation, a precursor of tryptophan 683 biosynthesis, and a key metabolite to reduce or even prevent IBD pathogenesis [106,107]. 684 Additionally, other functions involved in amino acid- and tryptophan metabolism, e.g. 685 686 Phenylalanine, tyrosine and tryptophan biosynthesis, were also enriched. Thus, aromatic amino acid biosynthesis appears to have a strong, and health relevant effect, as the enrichment 687 of amino acid metabolism is very prominent in control subjects. Interestingly, bacterial 688 functions involved in *Flagellar assembly* show a strong and consistent association with 689 healthy subjects as well (antagonistic to IBD) and may arise from the abundance of so-called 690 691 "silent" flagellins present in Lachnospiraceae, which have potential anti-inflammatory activity via TLR5 binding [108]. However, Lachnospiraceae derived flagellins display a 692 strong immune reactivity in CD patients [109,110], which may represent an aberrant response 693 driven by an already disturbed mucosal barrier, rather than a *de novo* reaction to members of 694 the Lachnospiraceae [111,109]. Clostridium clostridioforme (Clostridium XIVa) is highly 695 CD-specific and immunologically reactive according to our results and other studies 696 [112,113]. A recent study identified a strong and cross cohort IBD association of 697 698 C. clostridioforme with specific biosynthetic gene clusters, whose products lead to increased inflammation and mucosal barrier dysfunction [114]. C. clostridioforme strongly correlates 699 700 with the concentration of the potentially pro-inflammatory long chained fatty acid eicosatetraenoic acid/arachidonic acid (F20:4) [113], and its uptake is positively associated to 701 dysbiosis (e.g. long saturated: long unsaturated: lipoids) correlated with community 702

composition and dysbiosis. Furthermore eicosatetraenoic acid positively associated with CD-703 704 and UC-associated taxa, R. gnavus but also C. clostridioforme, whereas typical probiotic taxa showed a significant negative relationship with this metabolite [113]. In addition to its 705 immune- and inflammatory characteristics, this fatty acid possesses bactericidal activity and 706 707 the potential to disrupt bacterial cell membranes [115]. This might indicate that IBDassociated taxa might be able to metabolize and synthesize F20:4 and are less susceptible to it. 708 709 while it interferes with the growth health-associated species [113,114]. In contrast, the consumption of vitamins, long-chain carbohydrates, and long unsaturated fatty acids is 710 correlated with lower levels of dysbiosis [42,116]. Bacterial traits that are central to the 711 712 generation and integration of immune modulatory factors of gram-negative (Lipopolysaccharide biosynthesis) and gram-positive bacteria (Teichoic acid biosynthesis, 713 *Peptidoglycan biosynthesis*) on the bacterial surface are also consistently enriched among IBD 714 patients. Comparable patterns of these surface/capsular and membrane factors have also been 715 observed in a recent meta-analysis of various IBD cohorts [117]. 716

717

718 CONCLUSION

The KINDRED cohort is a prospective cohort study that collects biomaterial and various 719 types of data from IBD patients and their first- or second-degree relatives. The main aim of 720 the KINDRED cohort is to identify lifestyle factors as well as serum and stool markers 721 associated with the onset of the disease (in initially healthy relatives with a positive family 722 history for IBD) and to investigate the individual disease course in patients on a multiomic 723 724 level, integrating lifestyle, genetics, and microbial information. Using this multiomic dataset we identified strong and generalizable dysbiosis gradients, which correspond strongly with 725 726 IBD pathologies, physiological manifestations of inflammation (e.g. BSS, calprotectin, anti-GP2 and ASCA IgA/IgG), genetic risk for IBD and general risk of disease onset. Patterns of 727

overabundance and importance of various opportunistic pathogens (e.g., Enterobacteriaceae, 728 729 C. XIVa clostridioforme), in addition to consistent patterns of oralization, characterize IBD patients. Functionally, pathways involved in amino acid metabolism and flagellar assembly 730 are beneficial, while mucolytic functions are associated with IBD. Broad scale ecological 731 patterns point totipping-point dynamics being involved in the drastic state transitions of 732 communities into the chaotic communities characteristic for IBD (community variability, 733 community differentiation). However, some limitations are present in this study. Healthy 734 relatives were not examined in an examination center and all information about these 735 individuals were obtained through self-administered questionnaires. Another potential 736 737 weakness of the KINDRED cohort is its open design, where recruitment has run over a long 738 period of time (from 2013, and ongoing), with a slow increase of onset cases, and steady decrease of participants with time due to lack of compliance or withdrawal from the study 739 during the regular, yet only biennial follow-ups. 740

741

742 MATERIALS AND METHODS

Basic study design and cohort: The KINDRED cohort is a German-wide, prospective cohort 743 744 study that collected both, questionnaire data and biomaterials from IBD patients and their (affected and unaffected) family members. Despite great efforts to include as many family 745 members as possible, a focus has always been on unaffected individuals with a family history 746 of IBD. The recruitment of study participants started in October 2013 and is still ongoing. 747 Follow-up information and new biomaterial samples were collected prospectively at intervals 748 749 of approximately two years (Figure S1-S3). As of April 2021, the IBD Family Cohort has thus enrolled 1497 IBD patients together with 1813 (initially) non-affected first- or second-750 degree relatives from Germany (minimum age at inclusion: 7 years). Participants, including 751 752 the IBD patients, were asked to provide questionnaire data and biomaterials (blood, stool,

hair) at baseline and after every 2 years of follow-up (Table S1 & S2). The resulting patient 753 754 counts are shown in Table 1 and Figure 1A. In addition, physician-administered 755 questionnaires were collected from IBD patients to obtain physician-validated information, such as diagnosis, disease pattern/location, activity, and medication (Table S1). Using these 756 data, the Kiel IBD Family Cohort aims to facilitate the comprehensive molecular, clinical, 757 lifestyle, nutritional, and sociodemographic characterization of patients and high-risk 758 individuals, and to identify preclinical signs for the onset of IBD. Additional information on 759 eligibility criteria, enrollment, data and biomaterial collection, as well as data management, 760 and privacy protection is given in the Supplement of this article. A standard battery of 761 762 questionnaires was used to assess self-reported dietary behavior (12 month recall questionnaire) and metrics of well-being and quality of life (quality of life index, Fatigue 763 Severity Scale index), were also employed (see Supplement) [118–120]. Nutritional data were 764 adjusted by total energy consumption to decouple caloric consumption from diet composition. 765 Individuals with undefined or unclear IBD diagnosis but with intestinal inflammation (e.g. 766 suspected CD/UC, colitis) are summarized under the category uIBD (undefined IBD, Table 767 768 S3).

Ethics and human samples: The KINDRED cohort study protocol was approved by the ethics committee of the Medical Faculty of Kiel University (AZ A117/13). Every study participant provided written informed consent on forms that were age-adapted. For participants under the age of 18 years, informed consent must also be signed by their parents. When the participants reached the ages of 12 and 18 years a new informed consent (reconsent) form was signed by the participants themselves and, in the case of 12-year-old adolescents, by their parents.

A cohort of treatment naïve and newly diagnosed IBD patients in an active disease state from Malta (naïve : $N_{CD}=31$, $N_{UC}=25$), including a healthy control cohort ($N_{Contr.}=96$), was recruited

as described elsewhere [64]. In addition we included a Maltese patient cohort currently in disease remission and treatment (remission: $N_{CD}=32$, $N_{UC}=66$), as described recently [63].

Individuals from the Swedish Inception Cohort in IBD (SIC IBD) were included as treatment-780 781 naïve patients, between 20-77 years of age. Symptoms, such as diarrhea, abdominal pain, bloody or mucous stools for >2 weeks, were inclusion criteria. The final diagnosis of IBD was 782 established according to internationally accepted criteria including clinical, microbiological, 783 endoscopic, histological, and radiological evaluation (N_{CD}=17, N_{UC}=16). Patients with 784 gastrointestinal symptoms but without endoscopic and histological signs of IBD-associated 785 inflammation were considered symptomatic controls (SC, N_{sc}=16). In addition, 17 healthy 786 787 individuals were included as healthy controls (N_{contr}=16, one failed sequencing).

Physiological measurements: Calprotectin (indicator of intestinal inflammation) was 788 measured in fecal samples using a Bühlmann fCALTM ELISA kit (BÜHLMANN 789 LABORATORIES AG) and analyzed using SoftMax Pro Software (Molecular Devices). 790 791 ASCA IgA/IgG and anti-GP2 IgA/IgG were measured externally using ELISA (Medipan GmbH) including batchwise calibration samples. Occult fecal blood was determined by 792 793 PreventID® Haemo/HaptOccult (Preventis GmbH, Bensheim, Germany). Other 794 immunological measures (CRP Hb) were obtained during the initial examination using standard clinical tests. 795

796 Polygenic Risk Scores: GSA data were quality controlled via gwas-qc (https://github.com/ikmb/gwas-qc) not correcting for closely related individuals in the cohort 797 using hg19 (genome build 37) of the human genome and 1000 Genome reference set. 798 799 Potential sample mix ups and unclear relatedness patterns were manually checked and corrected if needed. Imputation was performed after chromosome wise transformation into 800 801 bgzip VCF files via plink2 [121]. Single VCF files were uploaded to 802 hybridcomputing.ikmb.uni-kiel.de/webservice/sites/, imputed and phased via EagleImp

32

(Genome build: GRCh37/hg19, Reference: 1000 Genomes Phase 3, r² filter: 0.1, allowed
reference swaps, and strand flips) [122].

To examine the genetic susceptibility of individuals in the KINDRED cohort for IBD and its 805 subtypes CD and UC we calculated Polygenic Risk Scores (PRS). GWAS summary statistics 806 were taken from the meta-analysis of IBD from Liu et al [20]. The summary statistics are 807 based on a total of 5956 CD and 6968 UC patients with an additional 21770 population of 808 controls with European ancestry. PRS were calculated with LDpred2 within the bigsnpr (v. 809 1.12.2) R package [123,36]. After quality control of the summary statistics [124] the method 810 calculates a posterior mean effect size based on linkage disequilibrium information and base 811 effect size for all remaining available markers in both data sets. We used the auto-method of 812 *LDpred2*, which automatically estimated the parameter sparsity p and the SNP heritability h^2 813 814 and did not require to tune hyper-parameters in the validation set.

Stool sample processing: DNA extraction, sequencing and bioinformatics processing of 16S
rRNA gene libraries from stool samples were performed as described previously in detail
[125].

Data processing: Data processing of 16S sequences was performed using DADA2 1.10 [126]
via the workflow for big datasets (<u>https://benjjneb.github.io/dada2/bigdata.html</u>,
https://github.com/mruehlemann/ikmb_amplicon_processing/blob/master/

dada2_16S_workow_with_AR.R) resulting in abundance tables of Amplicon Sequence
Variants (ASVs). All sequencing runs were handled separately for error correction, read
merging, and combined chimera detection. ASVs underwent taxonomic annotation using the
naïve Bayesian classifier implemented in DADA2 using the Ribosomal Database Project 16
release [127,128]. ASV sequences were aligned via NAST-alignment to the SILVA core
database and filtered for informative sites (constant gaps, constant bases) in mothur [129].
Phylogenetic tree construction on ASV alignment generated was carried out using FastTree

2.1 with the CAT substitution model with Γ-correction and improved accuracy, employing
more minimum evolution rounds for initial tree search [-spr 4], more exhaustive tree search [mlacc 2], and a slower initial tree search [-slownni] [130]. Unstratified KO categories of
metagenome predictions were generated using the native ASV abundances and sequences in
PICRUSt 2.5.0 using default workflows [131].

833 Statistical methods:

Alpha diversity: Species richness (Chao1), Simpson diversity (1-D), and phylogenetic alpha 834 diversity (Nearest Taxon Index [NTI], Net Relatedness Index [NRI]) were calculated and 835 836 analyzed in R 3.5.3.17-19. Phylogenetic measures of alpha diversity [Nearest Taxon Index (NTI), and Net Relatedness Index (NRI)] were derived using the *PhyloMeasures* package, 837 based on 999 permutations against a null model preserving relative species richness within the 838 communities [132–134] [NRI=-1 × (MPDobserved-mean (MPDrandom))/SD(MPDrandom); 839 NTI=-1 × (MNTDobserved-mean(MNTDrandom))/SD(MNTDrandom)]. Both metrics are 840 841 phylogenetic effect sizes, for which positive values indicate phylogenetic clustering, values close to zero indicate neutral or random community assembly, and negative values indicate 842 phylogenetic overdispersion, either over the whole phylogenetic tree (NRI) or across the 843 closest related species/tips of the phylogenetic tree (NTI). The relationships of physiological-844 and microbial inflammation markers/indices with alpha diversity were analyzed using linear 845 models after correcting for relevant covariates (LM: residuals(variable~gender+scaled BMI + 846 scaled Age) ~ IBD (Contr., CD, UC, IBD) * physiological variable). Model fits were 847 visualized via base R and *jTools* [135]. General correlation of MD with alpha diversity was 848 tested via simple linear models, segmented linear models (segmented), or polynomial linear 849 models and assessed via the AIC. 850

851 **Beta diversity:** Analyses were conducted via distance based (conditional) Redundancy 852 analyses and permutative ANOVA, as well as with a multivariate test for homogeneity of

variances (10000 permutations) [136,137] using Bray-Curtis dissimilarity (differential 853 854 abundance). Global and pairwise differences in community varaibility were assessed via permutation test of multivariate homogeneity of group dispersions (10'000 permutations, via 855 the *betadisper* function). Community clustering according to anthropometric, community 856 857 distances of naïve and rarefied communities were highly correlated and thus higher coverage naïve samples were used for analysis (Bray-Curtis: Mantel: r=0.9588, P<0.001; Procrustes: 858 859 m²12=0.06012, r=0.9695, P<0.001; Jaccard: Mantel: r=0.9941, P<0.001; Procrustes: m²12=0.006143, r=0.9969, P<0.001). 860

DMM community clustering: Community clustering was performed via Dirichilet Multinomial Mixture modeling as implemented in the R packages microbiome (*microbiome_1.20.0*) [138] and DirichletMultinomial (*DirichletMultinomial_1.40.0*) [139] after centered log ratio transformation (CLR) implemented in *compositions* [140]. The optimal number of clusters was determined via Laplace goodness of fit optimization in a range of 1-15 clusters.

867 Differential abundance analysis: Taxon abundances were filtered by having normalized counts of at least 5 among 1% of samples (DESeq2 median of ratios transformation). Negative 868 binomial GLMs with Wald tests as implemented in DESeq2 (including automated effect 869 filtering) were employed to detect differentially abundant taxa for each time point separately 870 as well as for all time points combined [141]. To reduce the effect of potential confounding 871 effects we included subject age, BMI and sex as covariates and in addition the time point 872 itself, for the combined dataset. P-values were adjusted via FDR and only comparisons 873 excluding the small subset of uIBD patients were investigated further (Contr./CD, Contr./UC, 874 CD/UC, Contr./all-IBD). 875

Abundance~sex+ BMI (centered-scaled) + age (centered-scaled) [+ time point (BL/F1/F2)] +
IBD pathology (Control, CD, UC, uIBD)

Abundance~sex+ BMI (centered-scaled) + age (centered-scaled) [+ time point (BL/F1/F2)] +
Health status (Control/[CD, UC, uIBD])

Similar methods were applied to investigate the functional characteristics of the bacterial communities, as based on imputed bacterial functions and pathways via PICRUSt2 [131]. To generalize the single KO associations, we performed Gene Set Enrichment Analyses using a function wise score ($-\log 10(P_{Wald-test}) \times sign(\log \text{ fold change})$) by multiplying the natural logarithm of P-values multiplied by the sign of fold change via clusterProfiler (4.4.4) using the *gseKEGG* function [47,142].

886 Taxon abundances were correlated with a reduced set of clinical variables (ASCA IgA, ASCA IgG, anti-GP2 IgA, anti-GP2 IgG, fecal calprotrectin, BSS) as well as polygenic risk scores 887 for IBD in general and for CD or UC in particular. CLR transformed species abundances were 888 correlated with core physiological measures via ppcor [143], combining the P-values of 889 Spearman-, Kendall-, and Pearson correlations via Brown's method to detect and incorporate 890 891 the most consistent associations across different association measures [144]. The resulting Pvalues were FDR corrected and Spearman ρ was used for visualization via *ComplexHeatmap* 892 (v2.14.0) [145]. 893

894 Dysbiosis score: Dysbiosis scores based on the distribution of bacterial community members were calculated following Gevers et al. (2014) (Microbial Dysbiosis index/MD-index) and the 895 more generalized General Microbiome Health Index (GMHI) as developed by Gupta et al. 896 (2020) [38,39]. For the MD-index we combined significant taxa abundant in either CD or UC 897 patients (uIBD not included) as compared to healthy/non-IBD cohort members at the baseline 898 899 time point of the KINDRED cohort [log1p(sums(abundance CD, abundance UC)) / log1p(sums(non-IBD))]. GMHI was trained on the relative abundances at the baseline time 900 point (training: 90%, testing: 10%) of the KINDRED cohort using code adapted from the 901 Dutch Microbiome Project 902
903 ("https://github.com/GRONINGEN-MICROBIOME-CENTRE/DMP/tree/main/gmhi").

Physiological and microbial inflammation markers/indices were analysed using linear models including relevant covariates (variable~gender+scaled BMI + scaled Age + IBD (Contr., CD, UC, IBD)), followed by stepwise model selection to minimize AIC without significant loss of fit. The correlation of the MD/GMHI with alpha diversity was assessed with linear and quadratic fits and the best fit was selected via minimal AIC for each time point. Model fits were visualized via *base* R and *jTools* [135].

Heritability analyses: To estimate the heritability of single communities in a rather 910 heterogeneous and patchy pedigree with many confounding variables we applied a recently 911 912 published approach employing linear mixed models, as implemented in *lme4atl* (*relatLmer*) [146]. Thus, we were able to incorporate fixed effects in our heritability estimates using a 913 kinship matrix based on reported pedigree information (kinship2) (Sinnwell et al., 2014) and 914 CLR transformed taxon abundances. Evaluating the models with and without covariates (AIC, 915 based on ML fit) allows us to further evaluate whether taxon heritability/family association is 916 917 influenced significantly by environmental factors or family relations alone. To assess patterns 918 among close relatives we categorized relatedness patterns (related (>1st degree), first degree (sibling, parent)) for comparison, as well as calculated distances between healthy family 919 920 members and diseased and eventually diseased individuals (onsets). Similar techniques were applied for the analyses of KO heritability, including subject age and sex as covariates. Gene 921 Set Enrichment Analyses were performed on K-numbers using a function wise score based on 922 full h^2 estimates via clusterProfiler (4.4.4) using the gseKEGG function [142]. Community-923 wide correspondence between taxonomic and functional community dissimilarity and 924 925 relatedness (kinship matrix, plink2 based "Identity by State" distance derived from imputed SNP sets) was assessed via PROCRUSTES tests (5000 permutations). 926

Network analyses: Networks were generated individually for healthy and IBD (UC, CD) 927 928 cohort subsets, as well as for the complete time point subsets. The node-based values (degree, betweenness, PageRank-index, eigenvalue-centrality, k-nearest neighbor degree) were 929 calculated in *igraph* 1.2.4.1 [147–149]. Network-wide measures include centrality based 930 assortativity [150], network diameter, radius, and size, density/clustering [151,152], and 931 natural connectivity [48]. To assess whether bacteria were more important than expected by 932 chance, observed centralities (mean of control subsamples) were compared against a 933 permuted set of networks (10,000 times, combined for control subsamples) via one-sided Z-934 tests. Graphlet (4-node) frequency correlation (orca v1.1-1, Spearman) based Euclidean 935 936 distance [153,154] and an edge sharing distance (frequency of shared pairwise correlations) to assess network similarity between the different subgroup networks (CD, UC, Contr., IBD at 937 baseline, follow-up 1, follow-up 2). 938

Onset association: To predict the binary outcomes of disease onset based on diversity 939 measures and physiological/clinical variables, we employed generalized linear models with a 940 binomial error structure and a "clog-log" link function ("complementary-log-log") as 941 implemented in MASS [155]. The nonsymmetric complementary log-log link function ("clog-942 log") was chosen, for its ability to better cope with unbalanced distributions between positive 943 944 and negative outcomes in the target variable [156]. Baseline samples with the addition of one follow-up 1 sample, which developed disease in the second follow-up, were used for 945 prediction (N_{onset}=7), in the context of all remaining baseline samples or only healthy baseline 946 controls. Models included either no covariates, or the established set of covariates (scaled age, 947 sex, scaled BMI). Model fits were visualized via base R and *jTools* [135]. 948

949 Models:

950 IBD-onset next time point (1/0)~ metric

951 IBD-onset next time point (1/0)~sex+ BMI (centered-scaled) + age (centered-scaled) +

952 metric/clinical variable

953 Data structure: BL (N_{onset}=4, N_{CD}=551, N_{UC}=438, N_{uIBD}=32, N_{contr.}=787); BL-controls (N_{onset}=4,

954 $N_{contr.}$ =787); BL+ (N_{onset} =7, N_{CD} =551, N_{UC} =438, N_{uIBD} =32, $N_{contr.}$ =787); BL-controls+ (N_{onset} =7,

955 N_{contr.}=787)

956

957 ACKNOWLEDGEMENTS

We would like to thank Ilona Urbach, Ines Wulf, and Tonio Hauptmann of the IKMB microbiome laboratory and the staff of the IKMB sequencing facilities for their excellent technical support. This study was supported by the Deutsche Forschungsgemeinschaft (DFG) Research Unit 5042 ("miTarget-The Microbiome as a Therapeutic Target in Inflammatory Bowel Diseases"), the University of Malta, and the University of Örebro. Special thanks go to all participants of the KINDRED cohort study for enabling such a unique prospective study.

964

965 **DECLARATIONS:**

Funding: The KINDRED cohort received funding from the German Research Foundation
(DFG) through Excellence Clusters "Inflammation at interfaces" (EXC 306) and "Precision
Medicine in Inflammation" (PMI; EXC 2167), as well as from the Research Unit miTarget
(FOR 5042). This study was also supported by a grant from the German Ministry of
Education and Research (01ZX1606A).

971 Conflicts of interest: The authors declare that they have no conflicts of interest related to this972 article.

Availability of data and material: All KINDRED cohort data are stored and managed by the 973 974 PopGen biobank at the Institute of Epidemiology at Kiel University, Germany, Researchers 975 can apply for data access to the KINDRED data by submitting a research proposal, including the scientific background, research question, success prospects, study design, potential 976 977 conclusions, and scientific collaborators of their study, at the local biobank P2N via the following form: http://www.uksh.de/p2n/Information+for+Researchers.html. Due to the 978 informed consent obtained from the participants, phenotypes, as well as genotyping and all 979 16S rRNA gene-sequencing data, can not be deposited publicly. 980

Raw sequence data and relevant meta-data can be accessed online under the accession number PRJEB44440 (Malta IBD cases in remission), PRJEB47161 (Malta treatment naive IBD cases), PRJEB47162 (Malta controls) [63,64]; and data of the Swedish SIC-IBD inception cohort will be made available under the accession number PRJEB77933 at the European Nucleotide Archive (https://www.ebi.ac.uk/ena/) after acceptance of this manuscript at a peerreviewed journal.

Ethics approval: The study was performed in accordance with the principles of the 987 Declaration of Helsinki. Approval was granted by the ethics committee of the Medical 988 Faculty of Kiel University (AZ A117/13). Ethical approval for the Maltese cohorts was 989 obtained from the University of Malta Research Ethics Committee (Ref 32/2017) and patients 990 were recruited from the gastroenterology outpatient clinic at Mater Dei Hospital, Malta 991 [63,64]. Ethical approval for the Swedish SIC-IBD cohort was obtained from the Uppsala 992 Regional Ethics Committee (2010/313) and suspected IBD patients and controls were 993 recruited from gastroenterological units at six Swedish hospitals. 994

995 Consent to participate: Informed consent was obtained from all individual participants
996 included in the study (or, in the case of children, from their parents). Consent for publication:
997 Not applicable.

40

998 Authors' contributions: GJ, SS, MK, CB, AF and WL designed the study; JE, GJ, and WL, 999 LT and KJ conducted the study; LT, KJ and PRa curated the data; PE, RK, JJ and DR 1000 contributed external samples and additional clinical analyses; PRa and IR analyzed the data; 1001 PRa, IR, CB, WL and AF drafted the paper; all authors take responsibility for the final 1002 content. All authors have read the manuscript, made significant intellectual contributions and 1003 approved the final version of the manuscript.

1004

1005 FIGURES

1006 Figure 1: (A) Individual transitions in the cohort between time points. The highlighted transitions are onset cases detected during the study's runtime ($N_{BL \rightarrow F1}=4$, $N_{F1 \rightarrow F2}=1$, 1007 $N_{F2 \rightarrow F3}=2$, $N_{F3 \rightarrow F4}=3$). (B) Analysis of selected physiological inflammation markers (ASCA) 1008 1009 IgA/IgG, Calprotectin, BSS) with respect to IBD condition and relevant covariates via linear models at baseline (see Table 1). Shown are only the optimal model results, after the model 1010 1011 selection procedures are shown. Pairwise differences with respect to average differences, or differences in slope are highlighted in the plots (# $P \le 0.1000$, * $P \le 0.0500$, ** $P \le 0.0100$, 1012 *** $P \leq 0.0010$). (C) The violin plot displays the average differences of genetic predisposition 1013 to CD, UC and IBD in general, as based on *LDpred2* derived PRS. The average differences in 1014 1015 PRS were tested via Wilcoxon rank tests contrasting healthy individuals, with healthy future onset cases (grey), CD patients (red), UC patients, and patients with undefined IBD (uIBD). 1016 1017 In particular, compared with those in healthy controls, the average risk of IBD is significantly and consistently greater in patients with CD and UC, as well as in patients with future-onset 1018 disease. (D) Scatterplots show the significant relationships between polygenic risk scores for 1019 CD (PRS-CD) and selected physiological inflammation markers, between PRS-CD and ASCA 1020 IgG by considering anthropometric covariates (linear model on residuals) or without 1021

1022 (Spearman correlation). Additional correlations of IBD- and UC-PRS with physiological1023 markers can be found in Figure S4 and Table S5.

1024

Figure 2: Taxon differential abundances and predictability. (A) Overview of individual 1025 phylum abundances across time points and health conditions in the KINDRED Cohort. (B) 1026 Differential abundance analyses of ASVs based on the sample time point (BL). Displayed are 1027 the log fold changes for each ASV clustered by genus classification, including standard errors 1028 of the fold changes as indicated by individual error bars. Color indicates the phylum 1029 1030 membership of the ASVs/Genera. DA only displays significant differential abundance for the respective comparison/contrast ($P_{FDR} \le 0.05$). (C) Partial correlation of CLR transformed taxon 1031 abundances with core physiological measures via ppcor [143], combining the P values of 1032 Spearman-, Kendall-, and Pearson correlations via Brown's method and corrected via FDR 1033 [144]. Correlations were adjusted for age, gender, and BMI and Spearman ρ is used to 1034 1035 visualize correlation strength between taxa and clinical measures ($\# P_{FDR} \leq 0.1000$, * $P_{FDR} \leq 0.0500$, ** $P_{FDR} \leq 0.0100$, *** $P_{FDR} \leq 0.0010$). Overlapping patterns of differential 1036 abundance for the respective taxa in the KINDRED cohort, Maltese-, and Swedish cohort is 1037 indicated in the bottom color bars. (D) Differences in species richness between healthy 1038 individuals, future onset cases, CD, UC, and uIBD cases (Wilcoxon test). Correlation of 1039 species richness with the microbial dysbiosis index (MD-index), which results in a negative, 1040 but non-linear relationship (optimal AIC based fit) between diversity and dysbiosis (BL 1041 (poly): $F_{2,1809}=226.97$, $P<2.2\times10^{-16}$, $adj.R^2=0.1997$; F1 (poly): $F_{2,645}=83.778$, $P<2.2\times10^{-16}$, 1042 *adj*. R^2 =0.2037; F2 (poly): $F_{2.536}$ =55.745, P<2.2×10⁻¹⁶, *adj*. R^2 =0.1691; LM). Also the 1043 relationship between alpha diversity and several IBD relevant clinical measures, shows 1044 significant relationships between alpha diversity and host physiology, in a disease condition 1045 specific manner (see Table S15, Figure S11). Pairwise differences with respect to average 1046

1047 differences, or differences in slope are highlighted in the plots (# $P \le 0.1000$, * $P \le 0.0500$, 1048 ** $P \le 0.0100$, *** $P \le 0.0010$).

1049

Figure 3: (A) Non-metric Multidimensional Scaling (NMDS) of Bray-Curtis distances among 1050 baseline samples, displaying the significant clustering by health conditions and significant 1051 1052 correlations of clinical inflammation measures with community distance (BL, see Table S16 1053 & Table S17). (B) NMDS displaying the gradient of community dysbiosis as expressed by MD-index [38], in parallel with clinical measures of inflammation and healthy onset cases 1054 1055 highlighted in red (*, develop IBD in F1). (C) Correlation of MD-index and the first NMDS axis showing a clear gradient of dysbiosis in the community. Onset cases are distributed in the 1056 range of standard deviation around the mean of the community dsitribution (NMDS1) and the 1057 1058 severity of dysbiosis (MD-index). (D) Community variability between health conditions as 1059 measured by the distance to the group centroid, is overall significantly different between 1060 health conditions ($F_{3,1808}$ =46.0315, P=0.00001, PERMANOVA), and significantly increased in 1061 CD and UC patients as compared to healthy controls (Table S19). (E) Principle coordinate analysis of German-, Swedish-, and Maltese samples, highlighting the transferrability of the 1062 1063 dysbiosis gradient across cohorts (MD-index derived from german samples), (F) as well as a common disease wise clustering of communities irrespective of sample origin. (G) 1064 Community variability between health/IBD conditions within and between the German-, 1065 Swedish-, and Maltese cohorts showing a common theme of increased variability in IBD 1066 1067 cases. (H) Mean differences of dysbiosis (MD-index derived from german samples) within and across cohorts, with the strongest differences between healthy and CD individuals. (I) 1068 1069 Scatterplots visualize the correlation of selected physiological inflammation markers with the 1070 microbial dysbiosis score [38], and show disease specific differences as compared to healthy control individuals. Pairwise differences with respect to average differences, or differences in 1071

slope are highlighted in the plots (see Figure S16, Table S18; $\# P \leq 0.1000$, $* P \leq 0.0500$, 1072 ** P<0.0100, *** P<0.0010). (J) Visualization of the explained variation of significant 1073 anthropometric variables as based on serial PERMANOVA of Bray-Curtis distances in all 1074 1075 three time points available and focused on physiological measures (Table S17), different reported pathologies of individuals (Table S21), use of pharmaceuticals (Table S22), and 1076 nutrient intake as derived from FFQ data (Table S23). Variables are displayed if they show 1077 significant clustering in at least one time point ($\# P_{FDR} \leq 0.1000$, $* P_{FDR} \leq 0.0500$, 1078 ** $P_{FDR} \leq 0.0100$, *** $P_{FDR} \leq 0.0010$). 1079

1080

Figure 4: (A) Community clusters of the microbial community at the baseline time point, 1081 1082 determined by Dirichilet Multinomial Mixture modelling (DMM) and optimal clustering was determined via Laplace goodness of fit optimization. (B) Overlay of the Microbial Dysbiosis 1083 score gradient (Gevers et al., 2014) and community clusters (outlines), including healthy 1084 onset patients at baseline (indicated by *). (C) Community clusters display a significantly 1085 elevated level of dysbiosis in clusters 2 and 3 (pairwise Wilcoxon tests), (D) as well as 1086 elevated levels of community variability in cluster-3 (PERMANOVA). (E) Non-metric 1087 Multidimensional Scaling (NMDS) of Bray-Curtis distances of PICRUSt2 based KO 1088 abundances among baseline samples (Douglas et al., 2020), displaying the gradient of 1089 community dysbiosis as expressed by the taxonomy based MD-index (Gevers et al., 2014), 1090 (F) and displaying the significant clustering by health conditions and significant correlations 1091 of clinical inflammation measures with community distance (see Table S16 & Table S17). 1092 1093 Healthy IBD onset patients are highlighted in red (*, patients who developed IBD by the next follow-up). (G) Community variability between health conditions as measured by the distance 1094 1095 to the group centroid, was significantly increased in CD and UC patients as compared to healthy controls (PERMANOVA, Table S19). (H) Density plots show the significant Gene 1096

1097 Set Enrichments [142] of differentially abundant PICRUSt2 based KOs, between controls, CD 1098 patients, and UC patients ($P_{FDR} \le 0.05$). Differential abundance was tested via *DESeq2* and the 1099 enrichment score was derived from the -log10(P-values)*direction of fold change (Table 1100 S23). Repeatedly detected metabolic pathways are highlighted in bold.

1101

Figure 5: (A) Spiec-Easi networks of baseline samples (N=1812). Bacterial nodes highlight 1102 significant differentially abundant ASVs in the network [157]. Bacteria not showing any 1103 1104 differential abundance patterns between IBD patients and healthy controls are signified via (●), bacteria overabundant in IBD (combined CD, UC, uIBD) via (■) and bacteria more 1105 1106 abudnant in controls are signified via (\blacktriangleright) . The barplot visualizes node centrality based on the 1107 number of connections (node degree) at the baseline time point. Colored boxes highlight corresponding ASV differential abundance patterns in KINDRED, external cohorts, and their 1108 association to IBD onset and remission. Significance of centralities is derived from Z-tests 1109 against a randomized networks (10'000). (B) Global network characteristics were derived 1110 from the baseline and disease specific sub-networks, which can be informative for stability 1111 1112 and structure of the respective networks (Wilcoxon-test healthy vs. CD/UC). Network metrics include centrality based assortativity [150], network diameter, radius, and size as well as 1113 density/clustering [151,152], and natural connectivity [48]. (C) Network similarity of disease 1114 and time point specific sub networks, as well as subnetworks of external cohorts (Malta, 1115 1116 Sweden) based on graphlet distance [153] and displayed via NMDS. Networks show a clear compositional difference between healthy and diseased networks (Control vs. IBD (incl. IBD 1117 1118 networks): $F_{1,18}=2.4144$, P=0.0412, $R^2=0.1183$, adj. $R^2=0.0693$; PERMANOVA). (D) Heritability estimates derived from the likelihood based method *lme4qtl* (Ziyatdinov et al., 1119 1120 2018) using either only kinship information with or without additional environmental and anthropometric covariates (\blacktriangle -incl. environmental covariates, \triangledown -no covariates). Only the 1121

- 1122 upper quartile of taxa are highlighted (based on h_{full}^2 estimate including environmental
- 1123 covariates). Additional information like differential abundance in IBD accross cohorts are
- 1124 depicted for each taxon (Figure S28A, Table S26).

1125

1126 TABLES

Table 1: Baseline characteristics of the IBD patients ($N_{individuals}=1868$) of the Kiel IBD Family Cohort. Values are mean \pm standard deviation or absolute

1128 counts. Abbreviations: CD, Crohn's disease; IBD, inflammatory bowel disease; UC, Ulcerative colitis, uIBD, undefined inflammatory bowel disease.

1129

		Baseline				Follow	w-up 1		Follow-up 2			
Characteristics	Control	CD	UC	uIBD	Control	CD	UC	uIBD	Control	CD	UC	uIBD
# Participants	791	551	438	32	362	174	105	7	295	146	92	6
Sex												
Male	316	175	166	13	140	57	38	1	103	52	34	0
Female	432	375	272	19	185	117	67	6	152	94	56	6
Age at baseline assessment, years	44.14±1 9.44	43.99±15. 58	46.42±14. 62	41.63±15. 11	45.60±19. 03	43.95±14. 63	48.64±14. 37	49.71±19. 72	47.56±18. 06	47.03±14. 23	48.65±14. 82	55±15.18
Age groups												
Children (7-11 years)	46	6	0	0	28	1	0	0	8	1	0	0
Adolescents (12-17 years)	47	24	8	2	33	11	0	0	11	3	0	0
Adults (≥18 years)	698	521	430	30	333	162	105	7	286	142	92	6
BMI (kg/m ²) average	24.98±5. 33	24.05±4.7 4	24.60±4.6 5	24.92±4.8 8	25.18±4.9 8	24.51±5.2 8	24.65±4.2 7	26.86±3.5 7	26.15±12. 33	24.45±4.7 1	24.99±4.0 9	24.00±5.3 0
BMI Children (7-11 yrs)	16.50±2. 47	14.78±1.8 3	-	-	17.97±2.6 8	14.18	-	-	16.89±0.2 4	16.66	-	-
BMI Adolescents (12-17 yrs)	20.18±3.	18.81±2.5	17.11±1.7	22.65±3.1	20.66±2.4	18.85±2.6	-	-	22.37±4.6	17.23±1.1	-	-

	18	4	2	3	0	4			2	5		
BMI Adults (≥18 years)	25.81±4. 92	24.36±4.6 0	24.74±4.5 8	25.07±4.9 8	25.70±4.8 1	24.96±5.1 5	24.65±4.2 7	26.86±3.5 7	26.36±12. 48	24.66±4.6 1	24.99±4.0 9	24.00±5.3 0
Smoking Status												
never smoked	392	260	200	18	181	83	50	4	147	71	46	4
smoked less than 3 months	65	29	32		26	9	8	-	15	5	4	0
smoked in the past	201	185	181	12	84	62	39	2	70	55	30	1
smoking now	87	76	25	1	30	19	6	1	20	14	8	0
Age at IBD diagnosis (yrs)	-	24.42±12. 22	29.94±13. 66	23.1±18.6 8	-	22.51±10. 51	26.74±10. 14	71	-	23.63±11. 17	28.06±13. 77	33.33±33. 72
Disease location for CD (multiple sites possible)												
not known	-	11	-	1	-	1	1	2	1	3	-	1
middle GI tract (proximal)	-	4	-	-	-	4	-	-	-	1	-	-
middle GI tract (distal)	-	9	1	-	-	6	-	-	-	2	-	-
upper GI tract	-	15	-	-	1	11	-	-	1	10	-	-
ileum	-	44	-	-	-	23	-	-	2	12	-	-
terminal ileum	2	145	1	2	-	67	1	-	8	51	1	1
ileum and colon	1	86	2	1	-	49	-	1	2	44	-	-
colon	2	75	16	6	-	44	6	3	2	32	-	3

perianal		30	1	1	-	15	-	-	1	8	-	-
Disease location for UC (multiple sites possible)												
not known	-	-	6	1	-	1	1	6	2	-	2	1
proctitis	-	-	43	-	1	2	12	-	3	-	16	-
left colon	1	-	83	1	-	1	33	-	5	-	23	-
pancolitis	2	-	128	3	-	3	47	-	2	1	33	-
Medication												
Yes	479	536	417	30	205	167	99	6	163	130	80	6
No	312	15	21	2	157	7	6	1	132	16	12	0
antidiarrhetics	0	57	41	2	0	29	11	0	5	34	7	0
antibiotics	133	142	99	10	67	41	27	2	28	39	18	1
antiinflammatory	7	470	364	27	2	155	84	6	14	103	59	5
Type of IBD medication (last 12 months)												
Immunosuppressives	3	96	78	4	1	47	16	1	5	32	17	1
Glucocorticoids	1	39	29	0	0	29	15	3	4	33	12	0
5484	3	30	109	6	0	43	50	4	7	37	46	5

Mesalazin	0	117	112	11	0	49	57	4		-	-	-
Sulfasalazin	0	24	16	0	0	12	4	0		-	-	-
AZA	0	99	42	5	0	40	13	1		-	-	-
Biologicals/'small molecules'	1	77	45	1	0	54	16	0	4	46	12	0
IBD surgery												
Yes	2	364	78	4	0	116	83	1	0	98	19	0
No	789	187	360	28	362	58	22	6	295	48	73	6
Number of future onsets (IBD next time point)	4	-	-	-	1	-	-	-	2	-	-	-

1130

1131

Table 2: Analysis of major physiological characteristics across time points using linear models. Results depicted are models after variable selection

1133 minimizing AIC.

								Me	ean	5	Slope
TP	Trait	Model Factors	DF	F	Р	adj R2	Comparison	Р	P(FDR)	Р	P(FDR)
BL	ASCA IgA	BMI#	1,750	3.5792	0.0589	0.1835	CD - Contr.	7.50×10 ⁻³³	4.50×10 ⁻³²	-	-
	(log)	IBD	3,750	56.6106	2.00×10 ⁻¹⁶		CD - uIBD	7.06×10 ⁻⁶	1.41×10 ⁻⁵	-	-
							CD - UC	1.54×10 ⁻¹⁸	4.62×10 ⁻¹⁸	_	-

						Contr uIBD	0.6907	0.6907	-	-
						Contr UC	0.3482	0.5223	-	-
						uIBD - UC	0.4621	0.5545	-	-
ASCA IgG	Age#	1,775	5.5172	0.0191	0.1684	CD - Contr.	3.26×10 ⁻²⁸	1.95×10 ⁻²⁷	-	-
(log)	IBD	3,775	52.0840	2.00×10 ⁻¹⁶		CD - uIBD	2.62×10 ⁻⁶	5.25×10 ⁻⁶	-	-
						CD - UC	5.15×10 ⁻²¹	1.55×10 ⁻²⁰	-	-
						Contr uIBD	0.3032	0.4548	-	-
						Contr UC	0.4175	0.4871	-	-
						uIBD - UC	0.4871	0.4871	-	-
GP2 IgA	Sex	1,744	0.0869	0.7682	0.0905	CD - Contr.	6.98×10 ⁻¹⁴	4.19×10 ⁻¹³	0.5056	0.7584
(log)	Age#	1,744	4.3479	0.0374		CD - uIBD	0.0808	0.1616	0.0099	0.0198
	BMI#	1,744	0.4423	0.5062		CD - UC	9.09×10 ⁻⁷	2.73×10 ⁻⁶	0.8492	0.8492
	IBD	3,744	20.5139	8.85×10 ⁻¹³		Contr uIBD	0.4227	0.5073	0.0040	0.0198
	Sex:Age#	1,744	10.1477	0.0015		Contr UC	0.2299	0.3449	0.7278	0.8492
	BMI#:IBD	3,744	2.8203	0.0381		uIBD - UC	0.7453	0.7453	0.0092	0.0198
GP2 IgG	Sex	1,770	1.3630	0.2434	0.0480	CD - Contr.	2.84×10 ⁻⁸	1.71×10 ⁻⁷	-	-
(log)	Age#	1,770	0.3528	0.5527		CD - uIBD	0.1108	0.2216	-	-
	IBD	3,770	11.3671	2.67×10 ⁻⁷		CD - UC	0.0001	0.0003	-	-

	Sex:Age#	1,770	9.3248	0.0023		Contr uIBD	0.8118	0.9654	-	-
						Contr UC	0.6145	0.9218	-	-
						uIBD - UC	0.9654	0.9654	-	-
CRP (X ^{1/4})	Age#	1,295	0.2114	0.6460	0.0323		-	-	-	-
(only CD & UC)	BMI#	1,295	9.7144	0.0020			-	-	-	-
	IBD	1,295	0.0050	0.9439			-	-	-	-
	Age#:IBD	1,295	4.0463	0.0452			-	-	-	-
HB (X ²)	Sex	1,414	123.8936	2.36×10 ⁻²⁵	0.2408		-	-	-	-
(CD & UC)	BMI#	1,414	10.0727	0.0016			-	-	-	-
Calprotectin (rel.)	Age#	1,1755	6.5053	0.0108	0.0576	CD - Contr.	7.58×10 ⁻²¹	4.55×10 ⁻²⁰	0.0091	0.0547
	IBD	3,1755	33.5156	6.19×10 ⁻²²		CD - uIBD	0.4827	0.5792	0.9471	0.9471
	Age#:IBD	3,1755	2.5284	0.0558		CD - UC	0.0240	0.0431	0.4795	0.7690
						Contr uIBD	0.0287	0.0431	0.5127	0.7690
						Contr UC	2.88×10 ⁻¹⁰	8.64×10 ⁻¹⁰	0.1388	0.4164
						uIBD - UC	0.9287	0.9287	0.8561	0.9471
Bristol stool score	Age#	1,874	33.4743	1.01×10 ⁻⁸	0.1825	CD - Contr.	1.50×10 ⁻³¹	8.97×10 ⁻³¹	0.0013	0.0076
	IBD	3,874	53.2308	2.20×10 ⁻¹⁶		CD - uIBD	0.0682	0.0861	0.6533	0.9478
	Age#:IBD	3,874	3.4956	0.0152		CD - UC	0.0031	0.0063	0.0772	0.2315

							Contr uIBD	0.0718	0.0861	0.7898	0.9478
							Contr UC	1.94×10 ⁻¹⁸	5.81×10 ⁻¹⁸	0.2316	0.4632
							uIBD - UC	0.3532	0.3532	0.9902	0.9902
F1	CRP (X ^{1/4} , CD & UC)	Sex	1,175	2.2744	0.1333	0.0072		-	-	-	-
	HB (X^2 , CD & UC)	Sex	1,197	38.7355	2.86×10-9	0.1601		-	-	-	-
	Calprotectin (rel.)	Age#	1,507	3.7867	0.0522	0.0921	CD - Contr.	4.54×10-9	2.73×10 ⁻⁸	0.0194	0.0583
		IBD	3,507	14.4469	4.81×10-9		CD - uIBD	0.6170	0.7404	0.0860	0.1290
		Age#:IBD	3,507	4.0004	0.0078		CD - UC	0.5625	0.7404	0.5011	0.5011
							Contr uIBD	0.2880	0.5760	0.2935	0.3521
							Contr UC	2.91×10 ⁻⁵	0.0001	0.0102	0.0583
							uIBD - UC	0.7708	0.7708	0.0508	0.1015
	Bristol stool score	Sex	1,314	4.2960	0.0390	0.0104		-	-	-	-
	QOL (relative)	Sex	1,593	5.1103	0.0242	0.1588	CD - Contr.	8.28×10 ⁻¹⁸	4.97×10 ⁻¹⁷	-	-
		Age#	1,593	23.4394	1.65×10 ⁻⁶		CD - uIBD	0.1088	0.1632	-	-
		BMI#	1,593	5.4685	0.0197		CD - UC	0.0016	0.0031	-	-
		IBD	3,593	26.7214	3.20×10 ⁻¹⁶		Contr uIBD	0.5548	0.5684	-	-
		Sex:BMI#	1,593	6.0564	0.0141		Contr UC	0.0001	0.0002	-	-
							uIBD - UC	0.5684	0.5684	-	-

0	$CRP (X^{1/4}, CD \& UC)$	Sex	1,106	0.3282	0.5679	0.0195		-	-	-	-
		BMI#	1,106	0.2690	0.6051			-	-	-	-
		Sex:BMI#	1,106	4.5680	0.0349			-	-	-	-
I	$HB(X^2, CD \& UC)$	IBD	1,142	3.7767	0.0539	0.0191		-	-	-	-
(Calprotectin (rel.)	IBD	2,144	6.4245	0.0021	0.0692	CD - Contr.	0.0009	0.0026	-	-
							CD - UC	0.2373	0.2373	-	-
							Contr UC	0.1120	0.1680	-	-
I	Bristol stool score	Sex	1,250	1.0378	0.3093	0.0173		-	-	-	-
		Age#	1,250	0.7100	0.4003			-	-	-	-
		Sex:Age#	1,250	5.6996	0.0177			-	-	-	-
(QOL (relative)	Age#	1,482	31.4038	3.53×10 ⁻⁸	0.1544	CD - Contr.	2.99×10 ⁻¹²	1.80×10 ⁻¹¹	0.0756	0.0908
		BMI#	1,482	2.0787	0.1500		CD - uIBD	0.4478	0.4478	0.0283	0.0566
		IBD	3,482	17.7663	5.94×10 ⁻¹¹		CD - UC	0.0169	0.0270	0.5291	0.5291
		Age#:IBD	3,482	3.5629	0.0142		Contr uIBD	0.0180	0.0270	0.0692	0.0908
							Contr UC	0.0005	0.0016	0.0271	0.0566
							uIBD - UC	0.1527	0.1833	0.0181	0.0566
I	FSS	Sex	1,479	8.0896	0.0046	0.0199		-	-	_	-
		Age#	1,479	0.0910	0.7630			-	-	-	-

Sex:Age# 1,479 4.5930 0.0326	-	-	-	-
------------------------------	---	---	---	---

1134 # centered and scaled

1135 Table 3: Analysis of alpha diversity patterns across time points, correcting for age, sex, and

1136 BMI.

						Pair	wise
Alpha diversity	Model	DF	F	Р	adj. R2	Contrast	P (adjusted)
Shannon	Age#	1,1727	4.1607	0.0415	0.1214	CD-Contr.	4.95×10 ⁻¹²
(effective)	BMI#	1,1727	0.0108	0.9174		CD-IBD	0.0483
	Sex	1,1727	2.0196	0.1555		CD-UC	5.16×10 ⁻⁶
	IBD diagnosis	3,1727	79.7519	2.56×10 ⁻⁴⁸		ContrIBD	0.1270
						ContrUC	4.99×10 ⁻¹²
						IBD-UC	0.8411
Chao	Age#	1,1727	4.1801	0.0411	0.1189	CD-Contr.	4.95×10 ⁻¹²
	BMI#	1,1727	0.0440	0.8338		CD-IBD	0.0921
	Sex	1,1727	1.3698	0.2420		CD-UC	4.18×10 ⁻⁷
	IBD diagnosis	3,1727	78.0602	2.37×10 ⁻⁴⁷		ContrIBD	0.0723
						ContrUC	4.99×10 ⁻¹²
						IBD-UC	0.9774
unweighted	Age#	1,1727	21.7176	0.0000	0.0146	CD-Contr.	0.1364
NRI	BMI#	1,1727	0.1274	0.7212		CD-IBD	0.7220
	Sex	1,1727	0.7269	0.3940		CD-UC	0.9318
	IBD diagnosis	3,1727	3.0502	0.0276		ContrIBD	0.9823
						ContrUC	0.0393
						IBD-UC	0.5945
unweighted	Age#	1,1727	18.6248	0.0000	0.0555	CD-Contr.	6.52×10 ⁻¹²
NTI	BMI#	1,1727	8.1830	0.0043		CD-IBD	0.9981
	Sex	1,1727	12.2254	0.0005		CD-UC	0.9177
	IBD diagnosis	3,1727	22.9073	1.53×10 ⁻¹⁴		ContrIBD	0.0588

							ContrUC	3.27×10-9
							IBD-UC	0.9783
F1	Shannon	Age#	1,599	3.7799	0.0523	0.1384	CD-Contr.	4.54×10 ⁻¹⁰
	(effective)	BMI#	1,599	0.2665	0.6059		CD-IBD	0.7611
		Sex	1,599	3.8384	0.0506		CD-UC	0.0026
		IBD diagnosis	3,599	31.7658	4.58×10 ⁻¹⁹		ContrIBD	0.4993
							ContrUC	0.0002
							IBD-UC	0.9988
	Chao	Age#	1,599	3.3731	0.0668	0.1091	CD-Contr.	4.54×10 ⁻¹⁰
		BMI#	1,599	0.8586	0.3545		CD-IBD	0.8398
		Sex	1,599	0.3035	0.5819		CD-UC	0.0081
		IBD diagnosis	3,599	25.1887	2.33×10 ⁻¹⁵		ContrIBD	0.5692
							ContrUC	0.0013
							IBD-UC	0.9975
	unweighted	Age#	1,599	2.3377	0.1268	0.0159	CD-Contr.	0.0231
	NRI	BMI#	1,599	4.1609	0.0418		CD-IBD	0.9981
		Sex	1,599	0.2207	0.6387		CD-UC	0.1840
		IBD diagnosis	3,599	3.0230	0.0292		ContrIBD	0.8141
							ContrUC	0.9979
							IBD-UC	0.8492
	unweighted	Age#	1,599	0.0932	0.7603	0.0657	CD-Contr.	1.71×10 ⁻⁷
	NTI	BMI#	1,599	12.7048	0.0004		CD-IBD	0.7954
		Sex	1,599	0.3129	0.5761		CD-UC	0.0060
		IBD diagnosis	3,599	11.8031	1.61×10 ⁻⁷		ContrIBD	0.0948
							ContrUC	0.6806
							IBD-UC	0.2089
F2	Shannon	Age#	1,483	2.1681	0.1415	0.1375	CD-Contr.	6.25×10 ⁻¹¹

(effective)	BMI#	1,483	0.0739	0.7859		CD-IBD	0.5878
	Sex	1,483	0.0128	0.9098		CD-UC	0.0080
	IBD diagnosis	3,483	27.2317	2.75×10 ⁻¹⁶		ContrIBD	0.7581
						ContrUC	0.0003
						IBD-UC	0.9958
Chao	Age#	1,483	5.4159	0.0204	0.1281	CD-Contr.	6.25×10 ⁻¹¹
	BMI#	1,483	2.8540	0.0918		CD-IBD	0.7797
	Sex	1,483	0.3818	0.5369		CD-UC	0.0010
	IBD diagnosis	3,483	23.0590	5.77×10 ⁻¹⁴		ContrIBD	0.6626
						ContrUC	0.0197
						IBD-UC	0.9929
unweighted	Age#	1,483	3.5979	0.0584	0.0179	CD-Contr.	0.1956
NRI	BMI#	1,483	2.1588	0.1424		CD-IBD	0.5201
	Sex	1,483	1.4772	0.2248		CD-UC	0.9997
	IBD diagnosis	3,483	2.5548	0.0547		ContrIBD	0.2385
						ContrUC	0.3879
						IBD-UC	0.5123
unweighted	Age#	1,483	3.0392	0.0819	0.0231	CD-Contr.	0.0585
NTI	BMI#	1,483	3.0373	0.0820		CD-IBD	0.5655
	Sex	1,483	0.0126	0.9105		CD-UC	0.9990
	IBD diagnosis	3,483	3.8270	0.0099		ContrIBD	0.2120
						ContrUC	0.1015
						IBD-UC	0.6040
(

scaled and centered

1141 **REFERENCES**

1. Burisch J, Jess T, Martinato M, Lakatos PL, on behalf of ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis [Internet]. 2013 [cited 2023 Mar 10];7:322–37. Available from: https://doi.org/10.1016/j.crohns.2013.01.010

Frolkis A, Dieleman LA, Barkema HW, Panaccione R, Ghosh S, Fedorak RN, et al.
 Environment and the inflammatory bowel diseases. Can J Gastroenterol J Can Gastroenterol.
 2013;27:e18-24.

 Nunes T, Fiorino G, Danese S, Sans M. Familial aggregation in inflammatory bowel disease: Is it genes or environment? World J Gastroenterol WJG [Internet]. 2011 [cited 2023 Mar 10];17:2715–22. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123468/

4. Zhao M, Burisch J. Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease. Dig Dis Sci. 2019;64:1759–69.

5. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology [Internet]. 2012;142:46-54.e42; quiz e30. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22001864

6. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol [Internet]. 2020 [cited 2023 Mar 10];5:17–30. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2468125319303334

7. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet [Internet]. 2017 [cited 2023 Mar 10];390:2769–78. Available from:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)324480/fulltext

8. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.

9. Schreiber S, Rosenstiel P, Franke A. [Genetic etiology of chronic inflammatory bowel disease]. Internist. 2014;55:156–64.

10. Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map—Recent advances on the etiology of inflammatory bowel disease. Semin Immunol [Internet]. 2009 [cited 2023 Mar 10];21:334–45. Available from:

https://www.sciencedirect.com/science/article/pii/S1044532309000955

11. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. Am J Gastroenterol. 2015;110:564–71.

 Capone K, Rosenberg HJ, Wroblewski K, Gokhale R, Kirschner BS. Change in Prevalence of Family History During Long-term Follow-up of Patients With Pediatric-onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2019;68:829–34.

Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TIA, Binder V. Familial
 Occurrence of Inflammatory Bowel Disease. N Engl J Med. 1991;324:84–8.

14. Santos MPC, Gomes C, Torres J. Familial and ethnic risk in inflammatory bowel disease.Ann Gastroenterol. 2018;31:14–23.

15. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet [Internet]. 2005;6:376–88. Available from: http://dx.doi.org/10.1038/nrg1607

16. Liu Z, Liu R, Gao H, Jung S, Gao X, Sun R, et al. Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. Nat Genet [Internet].2023 [cited 2024 May 13];55:796–806. Available from:

https://www.nature.com/articles/s41588-023-01384-0

17. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature.2012;491:119–24.

18. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Metaanalysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246–52.

19. Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. The Lancet [Internet]. 2016 [cited 2023 Mar 10];387:156–67. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00465-1/fulltext?rss
%3Dyes=

20. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet [Internet]. 2015 [cited 2023 Mar 10];47:979–86. Available from: https://www.nature.com/articles/ng.3359 21. Ballester MP, Martí D, Tosca J, Bosca-Watts MM, Sanahuja A, Navarro P, et al. Disease severity and treatment requirements in familial inflammatory bowel disease. Int J Colorectal Dis. 2017;32:1197–205.

22. Borren NZ, Conway G, Garber JJ, Khalili H, Budree S, Mallick H, et al. Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. J Crohns Colitis. 2018;12:525–31.

23. Kevans D, Silverberg MS, Borowski K, Griffiths A, Xu W, Onay V, et al. IBD GeneticRisk Profile in Healthy First-Degree Relatives of Crohn's Disease Patients. J Crohns Colitis.2016;10:209–15.

24. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet [Internet]. 2018 [cited 2024 Apr 11];19:581–90. Available from: https://www.nature.com/articles/s41576-018-0018-x

25. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature [Internet]. 2019;569:655–62. Available from: https://doi.org/10.1038/s41586-019-1237-9

26. Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, et al. The Integrative Human Microbiome Project. Nature [Internet]. 2019;569:641–8. Available from: https://doi.org/10.1038/s41586-019-1238-8

27. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, et al. Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease. Cell Host Microbe [Internet]. 2015;18:489–500. Available from: file://www.sciencedirect.com/science/article/pii/S1931312815003777 Torres J, Burisch J, Riddle M, Dubinsky M, Colombel J-F. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut [Internet]. 2016
 [cited 2024 Apr 19];65:1061–9. Available from: https://gut.bmj.com/content/65/7/1061

29. Argmann C, Hou R, Ungaro RC, Irizar H, Al-Taie Z, Huang R, et al. Biopsy and bloodbased molecular biomarker of inflammation in IBD. Gut [Internet]. 2022;0:1–17. Available from: https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-326451

30. Torres J, Petralia F, Sato T, Wang P, Telesco SE, Choung RS, et al. Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. Gastroenterology [Internet]. 2020;159:96–104. Available from: https://doi.org/10.1053/j.gastro.2020.03.007

31. Leibovitzh H, Lee S-H, Garay JAR, Espin-Garcia O, Xue M, Neustaeter A, et al. Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis. Gut [Internet]. 2023 [cited 2023 Aug 31];72:1462–71. Available from: https://gut.bmj.com/content/72/8/1462

32. Galipeau HJ, Caminero A, Turpin W, Bermudez-Brito M, Santiago A, Libertucci J, et al.Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis.Gastroenterology. 2021;160:1532–45.

33. Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, et
al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the
autoantigen of pancreatic antibodies in Crohn's disease. Gut [Internet]. 2009 [cited 2024 Jun
6];58:1620–8. Available from: https://gut.bmj.com/content/58/12/1620

34. Roggenbuck D, Reinhold D, Schierack P, Bogdanos DP, Conrad K, Laass MW. Crohn's disease specific pancreatic antibodies: clinical and pathophysiological challenges. Clin Chem Lab Med. 2014;52:483–94.

35. Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66:137–44.

Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. Bioinforma Oxf Engl.
 2021;36:5424–31.

37. Kuehbacher T, Rehman A, Lepage P, Hellmig S, Fölsch UR, Schreiber S, et al. Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease. J Med Microbiol.2008;57:1569–76.

38. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al.
The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe.
2014;15:382–92.

39. Gupta VK, Kim M, Bakshi U, Cunningham KY, Davis JM, Lazaridis KN, et al. A predictive index for health status using species-level gut microbiome profiling. Nat Commun [Internet]. 2020;11. Available from: http://dx.doi.org/10.1038/s41467-020-18476-8

40. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature [Internet]. 2018;555:623–8. Available from: http://dx.doi.org/10.1038/nature25979

41. Bennett M, Gilroy DW. Lipid Mediators in Inflammation. Microbiol Spectr [Internet].2016 [cited 2023 May 26];4:4.6.06. Available from:

https://journals.asm.org/doi/10.1128/microbiolspec.MCHD-0035-2016

42. Benus RFJ, Van Der Werf TS, Welling GW, Judd PA, Taylor MA, Harmsen HJM, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr [Internet]. 2010;104:693–700. Available from: http://dx.doi.org/10.1017/S0007114510001030

43. Vieira-Silva S, Sabino J, Valles-Colomer M, Falony G, Kathagen G, Caenepeel C, et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstructionassociated microbiota alterations across PSC/IBD diagnoses. Nat Microbiol [Internet]. 2019 [cited 2023 May 4];4:1826–31. Available from: https://www.nature.com/articles/s41564-019-0483-9

44. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatol Baltim Md. 2013;57:601–9.

45. Costea PI, Hildebrand F, Manimozhiyan A, Bäckhed F, Blaser MJ, Bushman FD, et al. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol [Internet]. 2017;3:8–16. Available from: https://doi.org/10.1038/s41564-017-0072-8

46. Frioux C, Ansorge R, Özkurt E, Ghassemi Nedjad C, Fritscher J, Quince C, et al.
Enterosignatures define common bacterial guilds in the human gut microbiome. Cell Host
Microbe [Internet]. 2023 [cited 2023 Jun 30]; Available from:
https://www.sciencedirect.com/science/article/pii/S1931312823002172

47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.

48. Jun W, Barahona M, Yue-Jin T, Hong-Zhong D. Natural Connectivity of Complex Networks. Chin Phys Lett [Internet]. 2010 [cited 2023 Aug 27];27:078902. Available from: https://dx.doi.org/10.1088/0256-307X/27/7/078902

49. Oehlers M, Fabian B. Graph Metrics for Network Robustness—A Survey. Mathematics [Internet]. 2021 [cited 2023 Jul 19];9:895. Available from: https://www.mdpi.com/2227-7390/9/8/895

50. Robertson LW, Chandrasekaran A, Reuning RH, Hui J, Rawal BD. Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum. Appl Environ Microbiol [Internet]. 1986 [cited 2023 May 13];51:1300–3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC239061/

51. Salaritabar A, Darvishi B, Hadjiakhoondi F, Manayi A, Sureda A, Nabavi SF, et al.
Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review.
World J Gastroenterol [Internet]. 2017 [cited 2023 Oct 26];23:5097–114. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537178/

52. Gupta A, Dhakan DB, Maji A, Saxena R, P.K. VP, Mahajan S, et al. Association of Flavonifractor plautii, a Flavonoid-Degrading Bacterium, with the Gut Microbiome of Colorectal Cancer Patients in India. mSystems. 2019;4:e00438-19.

53. Moll JM, Myers PN, Zhang C, Eriksen C, Wolf J, Appelberg KS, et al. Gut Microbiota Perturbation in IgA Deficiency Is Influenced by IgA-Autoantibody Status. Gastroenterology [Internet]. 2021 [cited 2024 Feb 20];160:2423-2434.e5. Available from: https://www.gastrojournal.org/article/S0016-5085(21)00458-3/fulltext

54. Alexander M, Ang QY, Nayak RR, Bustion AE, Sandy M, Zhang B, et al. Human gut bacterial metabolism drives Th17 activation and colitis. Cell Host Microbe. 2022;30:17-30.e9.

55. Banerjee S, Schlaeppi K, van der Heijden MGA. Keystone taxa as drivers of microbiome structure and functioning. Nat Rev Microbiol [Internet]. 2018 [cited 2024 Apr 17];16:567–76.
Available from: https://www.nature.com/articles/s41579-018-0024-1

56. Röttjers L, Faust K. Can we predict keystones? Nat Rev Microbiol. 2019;17:193.

57. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature [Internet]. 2010;464:59–65. Available from: http://dx.doi.org/10.1038/nature08821

58. Gordon H, Trier Moller F, Andersen V, Harbord M. Heritability in Inflammatory Bowel Disease: From the First Twin Study to Genome-Wide Association Studies. Inflamm Bowel Dis [Internet]. 2015 [cited 2023 May 3];21:1428–34. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450891/

59. Turpin W, Espin-Garcia O, Xu W, Silverberg MS, Kevans D, Smith MI, et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat Genet [Internet]. 2016;48:1413–7. Available from: http://dx.doi.org/10.1038/ng.3693

60. Rausch P, Rehman A, Künzel S, Häsler R, Ott SJ, Schreiber S, et al. Colonic mucosaassociated microbiota is influenced by an interaction of crohn disease and FUT2 (Secretor) genotype. Proc Natl Acad Sci U S A [Internet]. 2011;108:19030–5. Available from: http://www.pnas.org/content/early/2011/11/08/1106408108.abstract

61. Zaneveld JR, McMinds R, Thurber RV. Stress and stability: Applying the Anna Karenina principle to animal microbiomes. Nat Microbiol [Internet]. 2017;2:17121. Available from: https://doi.org/10.1038/nmicrobiol.2017.121

62. Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol [Internet]. 2017 [cited 2023 Jan 18];2. Available from: /pmc/articles/PMC5319707/

63. Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, et al. Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission.
Auchtung JM, editor. Microbiol Spectr [Internet]. 2022;10:e0061622. Available from: https://journals.asm.org/doi/10.1128/spectrum.00616-22

64. Rausch P, Ellul S, Pisani A, Bang C, Tabone T, Marantidis Cordina C, et al. Microbial Dynamics in Newly Diagnosed and Treatment Naïve IBD Patients in the Mediterranean. Inflamm Bowel Dis [Internet]. 2023 [cited 2023 Feb 7];1–15. Available from: https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izad004/7025776

65. Halfvarson J, Standaert-Vitse A, Järnerot G, Sendid B, Jouault T, Bodin L, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut [Internet]. 2005 [cited 2022 Oct 6];54:1237–43. Available from: www.gutjnl.com

66. Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, et al.
Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis
Patients Are Linked to Disease Course. Cell Host Microbe [Internet]. 2018;24:600-610.e4.
Available from: https://www.sciencedirect.com/science/article/pii/S1931312818304931

67. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–4.

68. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial

growth rates. Gut [Internet]. 2016 [cited 2024 Jan 31];65:57–62. Available from: https://gut.bmj.com/content/65/1/57

69. Boekhorst J, Venlet N, Procházková N, Hansen ML, Lieberoth CB, Bahl MI, et al. Stool energy density is positively correlated to intestinal transit time and related to microbial enterotypes. Microbiome [Internet]. 2022 [cited 2024 Apr 15];10:1–10. Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01418-5

70. Procházková N, Falony G, Dragsted LO, Licht TR, Raes J, Roager HM. Advancing human gut microbiota research by considering gut transit time. Gut [Internet]. 2023 [cited 2024 Apr 15];72:180–91. Available from: https://gut.bmj.com/content/72/1/180

71. Turpin W, Bedrani L, Espin-Garcia O, Xu W, Silverberg MS, Smith MI, et al.
Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. BMC Med Genet [Internet]. 2020 [cited 2023 May 14];21:1–8. Available from:

https://bmcmedgenet.biomedcentral.com/articles/10.1186/s12881-020-01115-w

72. Ellinghaus D, Bethune J, Petersen B-S, Franke A. The genetics of Crohn's disease and ulcerative colitis – status quo and beyond. Scand J Gastroenterol [Internet]. 2015 [cited 2024 Apr 19];50:13–23. Available from: https://doi.org/10.3109/00365521.2014.990507

73. Schirmer M, Stražar M, Avila-Pacheco J, Rojas-Tapias DF, Brown EM, Temple E, et al. Linking microbial genes to plasma and stool metabolites uncovers host-microbial interactions underlying ulcerative colitis disease course. Cell Host Microbe [Internet]. 2024 [cited 2024 Feb 19];32:209-226.e7. Available from:

https://www.sciencedirect.com/science/article/pii/S1931312823005085

74. Wegiel B, Otterbein L. Go Green: The Anti-Inflammatory Effects of Biliverdin
Reductase. Front Pharmacol [Internet]. 2012 [cited 2024 Apr 11];3. Available from:
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2012.00047/full

75. Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al.
Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell
[Internet]. 2016 [cited 2024 Feb 27];167:1125-1136.e8. Available from:
https://www.cell.com/cell/abstract/S0092-8674(16)31403-9

76. Rühlemann MC, Hermes BM, Bang C, Doms S, Moitinho-Silva L, Thingholm LB, et al. Genome-wide association study in 8,956 German individuals identifies influence of ABO histo-blood groups on gut microbiome. Nat Genet [Internet]. 2021;53:147–55. Available from: https://doi.org/10.1038/s41588-020-00747-1

77. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature [Internet]. 2008 [cited 2024 Mar 14];453:620–5. Available from: https://www.nature.com/articles/nature07008

78. Chu H, Khosravi A, Kusumawardhani IP, Kwon AHK, Vasconcelos AC, Cunha LD, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352:1116–20.

79. Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, et al. Genetic Determinants of the Gut Microbiome in UK Twins. Cell Host Microbe [Internet].
2016;19:731–43. Available from: http://dx.doi.org/10.1016/j.chom.2016.04.017

80. Valles-Colomer M, Blanco-Míguez A, Manghi P, Asnicar F, Dubois L, Golzato D, et al.
The person-to-person transmission landscape of the gut and oral microbiomes. Nature
[Internet]. 2023;614:125–35. Available from: https://doi.org/10.1038/s41586-022-05620-1

81. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell [Internet]. 2014;159:789–99. Available from: http://www.sciencedirect.com/science/article/pii/S0092867414012410

82. Schulfer AF, Battaglia T, Alvarez Y, Bijnens L, Ruiz VE, Ho M, et al. Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol [Internet]. 2018;3:234–42. Available from: http://dx.doi.org/10.1038/s41564-017-0075-5

83. Parker A, Romano S, Ansorge R, Aboelnour A, Le Gall G, Savva GM, et al. Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain. Microbiome [Internet]. 2022 [cited 2023 Sep 21];10:1–25. Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01243-w

84. Wang J, Kalyan S, Steck N, Turner LM, Harr B, Künzel S, et al. Analysis of intestinal microbiota in hybrid house mice reveals evolutionary divergence in a vertebrate hologenome. Nat Commun. 2015;6:6440.

85. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol [Internet]. 2012;10:323–35. Available from: http://dx.doi.org/10.1038/nrmicro2746

86. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A
Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances
Pathogen Susceptibility. Cell [Internet]. 2016 [cited 2024 Apr 8];167:1339-1353.e21.
Available from: https://www.sciencedirect.com/science/article/pii/S0092867416314647

87. Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen MAY, Bolte LA, et al.
Environmental factors shaping the gut microbiome in a Dutch population. Nature [Internet].
2022;604:732–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35418674

88. Rajilić-Stojanović M, Shanahan F, Guarner F, De Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013;19:481–8.

89. Berry D, Schwab C, Milinovich G, Reichert J, Ben Mahfoudh K, Decker T, et al. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J [Internet]. 2012;6:2091–106. Available from: http://dx.doi.org/10.1038/ismej.2012.39

90. Waters JL, Ley RE. The human gut bacteria Christensenellaceae are widespread,
heritable, and associated with health. BMC Biol [Internet]. 2019 [cited 2024 Apr 16];17:83.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819567/

91. Utter DR, He X, Cavanaugh CM, McLean JS, Bor B. The saccharibacterium TM7x elicits differential responses across its host range. ISME J [Internet]. 2020 [cited 2024 Apr 17];14:3054–67. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784981/

92. McLean JS, Bor B, Kerns KA, Liu Q, To TT, Solden L, et al. Acquisition and Adaptation of Ultra-small Parasitic Reduced Genome Bacteria to Mammalian Hosts. Cell Rep [Internet].
2020;32:107939. Available from: https://doi.org/10.1016/j.celrep.2020.107939

93. Hong M, Li Z, Liu H, Zheng S, Zhang F, Zhu J, et al. Fusobacterium nucleatum aggravates rheumatoid arthritis through FadA-containing outer membrane vesicles. Cell Host Microbe [Internet]. 2023 [cited 2023 May 12];31:798-810.e7. Available from: https://www.cell.com/cell-host-microbe/abstract/S1931-3128(23)00123-3

94. Engevik MA, Danhof HA, Ruan W, Engevik AC, Chang-Graham AL, Engevik KA, et al.
Fusobacterium nucleatum Secretes Outer Membrane Vesicles and Promotes Intestinal
Inflammation. mBio [Internet]. 2021 [cited 2023 May 12];12:e02706-20. Available from:
https://journals.asm.org/doi/10.1128/mBio.02706-20
95. Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, et al. Analysis of
Fusobacterium persistence and antibiotic response in colorectal cancer. Science [Internet].
2017 [cited 2023 Dec 10];358:1443–8. Available from:

https://www.science.org/doi/10.1126/science.aal5240

96. Rühlemann MC, Heinsen FA, Zenouzi R, Lieb W, Franke A, Schramm C. Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut. 2017;66:753–4.

97. Atarashi K, Suda W, Luo C, Kawaguchi T, Motoo I, Narushima S, et al. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science. 2017;358:359–65.

98. Madsen GR, Bertl K, Pandis N, Stavropoulos A, Burisch J. The Impact of Periodontitis on Inflammatory Bowel Disease Activity. Inflamm Bowel Dis. 2023;29:396–404.

99. Conte MP, Longhi C, Marazzato M, Conte AL, Aleandri M, Lepanto MS, et al. Adherentinvasive Escherichia coli (AIEC) in pediatric Crohn's disease patients: Phenotypic and genetic pathogenic features. BMC Res Notes [Internet]. 2014;7:748. Available from: https://doi.org/10.1186/1756-0500-7-748

100. Stecher B, Chaffron S, Käppeli R, Hapfelmeier S, Freedrich S, Weber TC, et al. Like will to like: Abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. PLoS Pathog [Internet]. 2010;6:e1000711. Available from: http://dx.doi.org/10.1371%2Fjournal.ppat.1000711

101. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, et al. Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature [Internet]. 2010 [cited 2023 Dec 12];467:426–9. Available from: https://www.nature.com/articles/nature09415

102. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae. Cell Host Microbe [Internet]. 2007;2:119–29. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1931312807001576

103. Vatanen T, Kostic AD, D'Hennezel E, Siljander H, Franzosa EA, Yassour M, et al.Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell[Internet]. 2016;165:842–53. Available from:

http://www.sciencedirect.com/science/article/pii/S0092867416303981

104. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis [Internet]. 2008 [cited 2024 Apr 19];14:1012–8. Available from: https://dx.doi.org/10.1002/ibd.20377

105. Ma S, Shungin D, Mallick H, Schirmer M, Nguyen LH, Kolde R, et al. Population structure discovery in meta-analyzed microbial communities and inflammatory bowel disease using MMUPHin. Genome Biol [Internet]. 2022 [cited 2024 Jun 11];23:1–31. Available from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-022-02753-4

106. Zelante T, Iannitti RG, Cunha C, DeLuca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity [Internet]. 2013;39:372–85. Available from: http://dx.doi.org/10.1016/j.immuni.2013.08.003

107. Nikolaus S, Schulte B, Al-Massad N, Thieme F, Schulte DM, Bethge J, et al. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases. Gastroenterology. 2017;153:1504-1516.e2. medRxiv preprint doi: https://doi.org/10.1101/2024.07.23.24310327; this version posted July 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

108. Clasen SJ, Bell MEW, Borbón A, Lee D-H, Henseler ZM, de la Cuesta-Zuluaga J, et al.
Silent recognition of flagellins from human gut commensal bacteria by Toll-like receptor 5.
Sci Immunol [Internet]. 2023 [cited 2023 Sep 22];8:eabq7001. Available from:
https://www.science.org/doi/10.1126/sciimmunol.abq7001

109. Alexander KL, Zhao Q, Reif M, Rosenberg AF, Mannon PJ, Duck LW, et al. Human Microbiota Flagellins Drive Adaptive Immune Responses in Crohn's Disease.
Gastroenterology [Internet]. 2021 [cited 2024 Apr 18];161:522-535.e6. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521006338

110. Lee S-H, Turpin W, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, et al. Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology [Internet]. 2021 [cited 2024 Apr 18];161:1540–51. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521032431

111. Turpin W, Lee S-H, Raygoza Garay JA, Madsen KL, Meddings JB, Bedrani L, et al.
Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease.
Gastroenterology [Internet]. 2020 [cited 2023 Jun 14];159:2092-2100.e5. Available from: https://www.sciencedirect.com/science/article/pii/S0016508520350216

112. Finegold SM, Song Y, Liu C, Hecht DW, Summanen P, Könönen E, et al. Clostridium clostridioforme: a mixture of three clinically important species. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2005;24:319–24.

113. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293–305. medRxiv preprint doi: https://doi.org/10.1101/2024.07.23.24310327; this version posted July 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

114. Elmassry MM, Sugihara K, Chankhamjon P, Camacho FR, Wang S, Sugimoto Y, et al.
A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies
disease-associated small molecules. bioRxiv [Internet]. 2024 [cited 2024 Apr
18];2024.02.07.579278. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10871352/

115. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microbiol Biotechnol. 2010;85:1629–42.

116. Pham VT, Fehlbaum S, Seifert N, Richard N, Bruins MJ, Sybesma W, et al. Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome- a pilot study. Gut Microbes. 2021;13:1–20.

117. Ning L, Zhou Y-L, Sun H, Zhang Y, Shen C, Wang Z, et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. Nat Commun [Internet]. 2023 [cited 2024 Apr 16];14:7135. Available from: https://www.nature.com/articles/s41467-023-42788-0

118. Dehne LI, Klemm C, Henseler G, Hermann-Kunz E. The German Food Code and Nutrient Data Base (BLS II.2). Eur J Epidemiol. 1999;15:355–9.

119. Nöthlings U, Hoffmann K, Bergmann MM, Boeing H. Fitting portion sizes in a selfadministered food frequency questionnaire. J Nutr. 2007;137:2781–6.

120. Wang J, Thingholm LB, Skiecevičie J, Rausch P, Kummen M, Hov JR, et al. Genomewide association analysis identifies variation in Vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet [Internet]. 2016;48:1396–406. Available from: http://dx.doi.org/10.1038/ng.3695 121. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Secondgeneration PLINK: Rising to the challenge of larger and richer datasets. GigaScience [Internet]. 2015;4:7. Available from: http://www.gigasciencejournal.com/content/4/1/7

122. Wienbrandt L, Ellinghaus D. EagleImp: fast and accurate genome-wide phasing and imputation in a single tool. Bioinforma Oxf Engl. 2022;38:4999–5006.

123. Privé F, Aschard H, Ziyatdinov A, Blum MGB. Efficient analysis of large-scale genomewide data with two R packages: bigstatsr and bigsnpr. Bioinforma Oxf Engl. 2018;34:2781–7.

124. Privé F, Arbel J, Aschard H, Vilhjálmsson BJ. Identifying and correcting for misspecifications in GWAS summary statistics and polygenic scores. HGG Adv. 2022;3:100136.

125. Thingholm LB, Bang C, Rühlemann MC, Starke A, Sicks F, Kaspari V, et al. Ecology impacts the decrease of Spirochaetes and Prevotella in the fecal gut microbiota of urban humans. BMC Microbiol [Internet]. 2021;21:276. Available from: https://doi.org/10.1186/s12866-021-02337-5

126. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2:
High-resolution sample inference from Illumina amplicon data. Nat Methods [Internet].
2016;13:581–3. Available from: http://dx.doi.org/10.1038/nmeth.3869

127. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naïve Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol [Internet]. 2007;73:5261–7. Available from:

http://aem.asm.org/cgi/content/abstract/73/16/5261

128. Lan Y, Wang Q, Cole JR, Rosen GL. Using the RDP classifier to predict taxonomic novelty and reduce the search space for finding novel organisms. PLoS ONE [Internet]. 2012;7:e32491. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0032491

129. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al.
Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol [Internet].
2009;75:7537–41. Available from: http://aem.asm.org/cgi/content/abstract/AEM.01541-09v1

130. Price MN, Dehal PS, Arkin AP. FastTree 2 - Approximately maximum-likelihood treesfor large alignments. PLoS ONE [Internet]. 2010;5:e9490. Available from:http://dx.doi.org/10.1371%2Fjournal.pone.0009490

131. Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al.
PICRUSt2 for prediction of metagenome functions. Nat Biotechnol [Internet]. 2020;38:685–
8. Available from: https://doi.org/10.1038/s41587-020-0548-6

132. Webb CO, Ackerly DD, McPeek MA, Donoghue MJ. Phylogenies and community ecology. Annu Rev Ecol Syst [Internet]. 2002;33:475–505. Available from: http://www.annualreviews.org/doi/abs/10.1146/annurev.ecolsys.33.010802.150448

133. Kembel SW, Cowan PD, Helmus MR, Cornwell WK, Morlon H, Ackerly DD, et al.Picante: R tools for integrating phylogenies and ecology. Bioinformatics [Internet].2010;26:1463–4. Available from:

http://bioinformatics.oxfordjournals.org/cgi/content/abstract/26/11/1463

134. Tsirogiannis C, Sandel B. PhyloMeasures: a package for computing phylogenetic biodiversity measures and their statistical moments. Ecography [Internet]. 2016;39:709–14.Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ecog.01814

135. Long JA. jtools: Analysis and Presentation of Social Scientific Data [Internet]. 2022. Available from: https://cran.r-project.org/package=jtools

136. Legendre P, Andersson MJ. Distance-based redundancy analysis: Testing multispecies responses in multifactorial ecological experiments. Ecol Monogr. 1999;69:1–24.

137. Anderson MJ, Ellingsen KE, McArdle BH. Multivariate dispersion as a measure of beta diversity. Ecol Lett [Internet]. 2006;9:683–93. Available from:

http://dx.doi.org/10.1111/j.1461-0248.2006.00926.x

138. Lahti L, Shetty S. Tools for microbiome analysis in R [Internet]. 2022. Available from: http://microbiome.github.io/microbiome

139. Holmes I, Harris K, Quince C. Dirichlet multinomial mixtures: Generative models for microbial metagenomics. PLoS ONE [Internet]. 2012;7:e30126. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0030126

140. van den Boogaart KG, Tolosana-Delgado R, Bren M. compositions: Compositional Data Analysis [Internet]. 2023. Available from: https://CRAN.R-project.org/package=compositions http://www.stat.boogaart.de/compositions/

141. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol [Internet]. 2014;15:550. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302049/

142. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS J Integr Biol [Internet]. 2012;16:284–7.Available from: https://www.liebertpub.com/doi/abs/10.1089/omi.2011.0118

143. Kim S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation
Coefficients. Commun Stat Appl Methods [Internet]. 2015 [cited 2024 Feb 7];22:665–74.
Available from: http://www.csam.or.kr/journal/view.html?doi=10.5351/CSAM.2015.22.6.665

144. Brown MB. 400: A Method for Combining Non-Independent, One-Sided Tests of Significance. Biometrics [Internet]. 1975 [cited 2024 Feb 7];31:987–92. Available from: https://www.jstor.org/stable/2529826

145. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics [Internet]. 2016 [cited 2024 Apr 3];32:2847–
9. Available from: https://doi.org/10.1093/bioinformatics/btw313

146. Ziyatdinov A, Vázquez-Santiago M, Brunel H, Martinez-Perez A, Aschard H, Soria JM. lme4qtl: linear mixed models with flexible covariance structure for genetic studies of related individuals. BMC Bioinformatics [Internet]. 2018 [cited 2023 Apr 3];19:1–5. Available from: https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-018-2057-x

147. Page L, Brin S. The anatomy of a large-scale hypertextual Web search engine. Comput Netw. 1998;30:107–17.

148. Freeman LC. Centrality in social networks conceptual clarification. Soc Netw.1978;1:215–39.

149. Csardi G, Nepusz T. The igraph software package for complex network research. InterJournal Complex Syst. 2006;1695.

150. Newman MEJ. Assortative Mixing in Networks. Phys Rev Lett [Internet].2002;89:208701. Available from:

http://journals.aps.org/prl/abstract/10.1103/PhysRevLett.89.208701

151. Wasserman S, Faust K. Social Network Analysis: Methods and Applications. Cambridge University Press; 1994.

152. West DB. Introduction to Graph Theory. Prentice Hall; 2001.

153. Yaveroğlu ÖN, Malod-Dognin N, Davis D, Levnajic Z, Janjic V, Karapandza R, et al. Revealing the Hidden Language of Complex Networks. Sci Rep [Internet]. 2014 [cited 2024 Apr 9];4:4547. Available from: https://www.nature.com/articles/srep04547

154. Hočevar T, Demšar J. Computation of Graphlet Orbits for Nodes and Edges in Sparse Graphs. J Stat Softw [Internet]. 2016 [cited 2023 May 9];71:1–24. Available from: https://doi.org/10.18637/jss.v071.i10

155. Venables WN, Ripley BD. The S Language. Mod Appl Stat S [Internet]. New York, NY: Springer New York; 2002. p. 41–68. Available from: http://dx.doi.org/10.1007/978-0-387-21706-2_3

156. Zuur AF, Ieno EN, Walker NJ, Saveliev AA, Smith GM. GLM and GAM for Absence– Presence and Proportional Data. Mix Eff Models Ext Ecol R [Internet]. New York, NY: Springer New York; 2009. p. 245–59. Available from: http://dx.doi.org/10.1007/978-0-387-87458-6_10

157. Kurtz ZD, Müller CL, Miraldi ER, Littman DR, Blaser MJ, Bonneau RA. Sparse and Compositionally Robust Inference of Microbial Ecological Networks. PLoS Comput Biol [Internet]. 2015;11:e1004226. Available from:

http://dx.doi.org/10.1371%2Fjournal.pcbi.1004226











Candidatus Saccharibacteria

Fusobacteria